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ABSTRACT OF DISSERTATION

THE EFFECTS OF LOBELINE ON METHAMPHETAMINE-INDUCED
CONDITIONED PLACE PREFERENCE AND DOPAMINERGIC ALTERATIONS IN
THE NUCLEUS ACCUMBENS SHELL
Previous research has suggested that lobeline, a plant alkaloid derived from
Lobelia inflate, has potential to be an efficacious pharmacotherapy for the treatment
of methamphetamine dependence. In addition to attenuating methamphetamineinduced dopaminergic alterations in vitro, lobeline has been shown to decrease the
primary rewarding effects and discriminative stimulus properties of
methamphetamine in rats. It is of clinical interest to assess the utility of lobeline to
decrease methamphetamine conditioned cues as these cues have been shown to
significantly contribute to relapse.
The current studies assessed the ability of lobeline to block the acquisition
and expression of methamphetamine-induced conditioned place preference in rats.
Lobeline blocked the acquisition of methamphetamine-induced conditioned place
preference when a low dose of methamphetamine was used during conditioning.
However, this blockade was surmounted with higher doses of methamphetamine.
Furthermore, the expression of methamphetamine-induced conditioned place
preference is attenuated following repeated administration, indicating that lobeline
not only blocks the primary reinforcing effects of methamphetamine, but it also
blocks the environmental cues that become associated with drug administration.
These results provide further evidence that lobeline may be an efficacious treatment
for methamphetamine dependence.
The rewarding properties of psychostimulants are thought to be mediated, at
least in part, by the nucleus accumbens shell. The effects of lobeline on
methamphetamine-induced alterations in this dopaminergic region were assessed
using microdialysis in rats. Acute lobeline did not have an effect on the
methamphetamine-induced increases in dopamine, indicating that repeated lobeline
administration may be more efficacious. Interestingly, lobeline potentiated the
methamphetamine-induced decrease of the dopamine metabolite, DOPAC. These
results suggest that acute lobeline may function to redistribute vesicular dopamine
pools within the terminal bouton.
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CHAPTER ONE
Introduction

Methamphetamine Dependence: Current Trends and Treatments.
The negative impact that methamphetamine availability has had on our
society is far-reaching. Methamphetamine is commonly synthesized in clandestine
laboratories using extremely caustic chemicals, which can readily create dangerous
situations including environmental contamination, explosions, and fires. Mere
exposure to these laboratories can result in negative health consequences.
However, the health consequences apparent in individuals that habitually use
methamphetamine can be devastating as these individuals are at increased risk for
unsafe sexual behaviors, cardiovascular problems, convulsions, and potentially
long-lasting psychotic behavior (NIDA, 2007b).
Despite efforts to curb methamphetamine production and use, a 2007
telephone survey of 500 county law enforcement officers (sheriffs) from 43 states
indicated that 47.5% of the sheriffs surveyed reported methamphetamine as the
most problematic drug of abuse in their county (NACO, 2007). While the number of
methamphetamine laboratories seized by officials peaked in 2003 and has steadily
decreased in recent years, the availability of methamphetamine has not decreased
as evidenced by 80% of the sheriffs surveyed reporting that the availability of the
drug has remained the same or increased in the last year (DEA; NACO, 2007).
Although the stereotypic methamphetamine abuser is a white male between 18 and
30 yrs old, an increased number of adolescents, women and ethnic minorities are
using methamphetamine (NACO, 2007). Additionally, recent reports from NIDA’s
2006 Monitoring the Future Survey indicate that crystal methamphetamine use
among young adults has not decreased over the last four years (NIDA, 2007a).
These epidemiological data illustrate the persistent use of methamphetamine in the
United States.
Currently, there are few options available for treating methamphetamine
dependence. Participation in behavioral therapies such as contingency
management programs have been shown to promote abstinence above that of
standard or no treatment (Prendergast, Podus, Finney, Greenwell, & Roll, 2006;
Roll et al., 2006; Shoptaw et al., 2005). In addition to behavioral therapies, efforts
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have been underway to identify an efficacious pharmacotherapy to aid in treating
methamphetamine dependence. A recent review highlights possible approaches
that may be utilized in the development of a pharmacotherapy including
immunotherapy and novel medications that would alter methamphetamine
pharmacodynamics (Vocci & Appel, 2007). Potential therapeutic targets include the
vesicular monoamine transporter, the dopamine transporter, dopamine receptors,
as well as GABA(Gamma-aminobutyric acid)ergic, glutamatergic, serotinergic,
endogenous opioid, and endocannabinoid pathways (Vocci & Appel, 2007).
Identification of a useful pharmacotherapy to aid in treating physiological alterations
that result from methamphetamine dependence may allow for better outcomes
following behavioral therapies (Ling, Rawson, Shoptaw, & Ling, 2006). Research
efforts to identify and develop an efficacious pharmacological aid for the treatment
of methamphetamine dependence are ongoing.

Pharmacokinetics of Methamphetamine
Rodent models are often employed to study various neurochemical and
behavioral aspects of psychoactive substance administration and have afforded an
improved understanding of potential mechanisms underlying the rewarding effects
of methamphetamine. In rodent models, psychoactive drugs are typically
administered intravenously, subcutaneously or intraperitoneally. While humans
administer methamphetamine intravenously, it is also commonly administered
intranasally and by inhalation of the smoke that results from heating it. In rats, the
plasma concentration of methamphetamine (3 mg/kg) reaches a maximum level
faster following intraperitoneal (5 – 10 min) administration than following
subcutaneous administration (20 – 30 min); however, ~42 % of methamphetamine
administered via intraperitoneal injection is subject to first-pass metabolism
(bioavailability ~52 %), whereas the bioavailability is 100% following intravenous
and subcutaneous injection (Gentry et al., 2004). While intravenous administration
provides 100% bioavailability in humans, the bioavailability of methamphetamine is
lower with other routes of administration, such as intranasal (79%) and smoked
(67%; Harris et al., 2003). Following a single administration of methamphetamine
that results in equivalent peak plasma concentrations in rat and human, the
elimination half-life is ~70 min and ~ 12 hr, respectively (Cho, Melega, Kuczenski, &
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Segal, 2001; Cook et al., 1993). Although most of the information available on
methamphetamine pharmacokinetics is derived from male subjects, there is
evidence that there are sex differences in methamphetamine serum levels achieved
following intravenous administration in rats; further characterizations of sex
differences with regard to pharmacokinetics warrants further investigation given the
increased use among women (Milesi-Halle, Hendrickson, Laurenzana, Gentry, &
Owens, 2005). Differences in the bioavailability of a methamphetamine across
routes of administration and the faster elimination of drug in rodents compared to
human should be taken into careful consideration when evaluating findings from
preclinical research.

Mechanisms of Drug Dependence
Theoretical Framework
The processes involved in learning and memory make it possible for an
individual to survive in their environment. One theoretical framework for drug
addiction suggests that the neurochemical consequences of psychoactive drug
administration may result in maladaptive learning. Associations learned during
repeated drug administration result in a distinct behavioral pattern involving an
incredibly high motivation to obtain drugs and an inability to abstain from
administering them, despite health and social consequences (Di Chiara, 1999;
Hyman & Malenka, 2001). There are several dissociable types of learning that are
affected by repeated exposure to psychostimulants, including associative
(instrumental and classical conditioning), non-associative (habituation and
sensitization), and procedural (skills and habits). Many of these learning processes
rely on the same neurobiological mechanisms that are altered following exposure to
psychoactive substances. It has been suggested that the milieu of drug-induced
neurobiological alterations ultimately results in abnormal, maladaptive rewardrelated learning (Kelley, 2004). Investigating the interactions of psychostimulantinduced neurobiological changes and reward learning may afford an efficacious
treatment for drug dependence that includes synergistic behavioral and
pharmacological interventions.
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Neuroanatomical and Neurochemical Aspects of Methamphetamine
Dependence
Techniques
Decades of research have provided insight into the neurobiological
mechanisms of learning that are thought to be altered following exposure to
psychoactive substances by utilizing various in vitro and in vivo methodologies. For
instance, anatomical lesions or inactivation of particular neurotransmitter systems
within a specific brain region prior to evaluation of a behavioral response can
provide information on the importance of that region for various behaviors and/or
neurotransmitter levels in other interconnected brain areas. Retrograde and
anterograde labeling of neurons has characterized neuronal pathways from one
brain region to another, as well as connections within specific brain structures. In
addition, receptor binding techniques can be used to identify and quantify specific
receptor subtypes distinct to specific brain regions. Electrically or pharmacologically
evoked neurotransmitter release can be assessed in several different assays and
provides insights into endogenous neuronal responses. Analysis of
neurotransmitter levels from dissected brain tissue or microdialysis samples using
high performance liquid chromatography with electrochemical detection (HPLC-EC)
has provided useful information about neurotransmitter levels within specific brain
regions following pharmacological and behavioral manipulations. Using receptor
selective agonists and antagonists in combination with these techniques can reveal
detailed information on the contribution of specific neurotransmitter systems or
receptor subtypes on the rewarding effects of a psychoactive drug.
In vivo microdialysis has provided a wealth of information about phasic levels
of monoamines in the mesocorticolimbic pathways in response to psychoactive
drugs. With this technique, rodents are implanted with a guide cannula and stylet
that terminates a few millimeters dorsal to the brain region of interest using
stereotaxic surgical techniques. Following 5-7 days of recovery, a microdialysis
probe, which snaps into the guide cannula, is implanted 4-24 hr prior to an
experimental manipulation. The probe has an inlet and outlet tube that allows
perfusion of artificial cerebrospinal fluid into and dialysate fluid out of a specified
brain region, usually at a rate of ~1 µl/min. At the end of the plastic probe is a 2
mm, semi-permeable membrane across which only small (up to 30 kD) endogenous
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molecules can diffuse. Before the experimental manipulation begins, the
concentration of molecules inside and outside (i.e. the extracellular space) of the
probe reach equilibrium as a result of diffusion down their concentration gradient
(Zhang & Beyer, 2006). The dialysate fluid is collected at set time intervals (usually
20 min) following an experimental manipulation and subsequently analyzed using
high HPLC-EC. Since baseline samples are collected for each animal,
experimental data is generally represented as a percent of baseline and the amount
of neurotransmitter represented is derived from external standards. In order to
determine the actual concentration of the analyte of interest in vivo, a quantitative
microdialysis technique known as no-net-flux is often used (Parsons & Justice,
1994). With this method, several concentrations of the analyte of interest are
perfused through the microdialysis probe and the dialysate samples are then
analyzed. The concentration at which the perfusate and the dialysate are equal is
the point of no-net flux, which estimates the concentration of the analyte in the
extracellular space (Watson, Venton, & Kennedy, 2006).
By analyzing the microdialysis samples with HPLC-EC, the concentration of
catecholamines, in addition to several other endogenous molecules, can be
determined. In this assay, the microdialysis sample can be introduced via injection
into the mobile phase, which is continuously pumped under pressure through a
stationary phase, or column, where the analytes of interest are eluted based on
their interactions with these two phases. The mobile phase then carries the
analytes to the electrochemical detector where a potential is applied and the
analytes are oxidized or reduced and the resulting free electron is recorded as a
change in current, which can be further characterized by computer software. Due to
the sample volume required for analysis with HPLC-EC, usually ~20 µl,
microdialysis with HPLC-EC is useful when assessing an overall increase in
monoamine levels across 20 min; however, the temporal resolution does not allow
for sec-by-sec analysis of neurochemical changes as can be obtained with
voltammetry (Westerink, 1995). However, information provided by voltammetry
experiments does not provide the level of sensitivity provided by HPLC-EC
(Westerink, 1995). Combinations of the aforementioned techniques in preclinical
research designs can provide useful insights into the neurochemical mechanisms
underlying the addictive properties of psychostimulants.
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Neurocircuitry and Neurotransmitter Systems
Specific anatomical locations in brain have been associated with the primary
reinforcing effects of psychostimulants and reward-related learning including: (1) the
nucleus accumbens, which is an important region for reward and motor integration;
(2) the ventral tegmental area, which is activated by reward and unpredicted events;
(3) the prefrontal cortex, which is employed for executive function, impulse control,
and decision making; (4) the ventral pallidum, which regulates voluntary motor
output; (5) the amygdala, which is essential for emotional processing and reward
learning; and (6) the hippocampus, which is critical for memory and detecting
novelty (Bardo, 1998). These brain regions communicate with one another through
various pathways (Ikemoto, 2007; Kalivas & O'Brien, 2007; Kelley, 2004; Kelley &
Berridge, 2002). Dopaminergic cell bodies within the ventral tegmental area project
axons to several forebrain regions including the prefrontal cortex, nucleus
accumbens, and the basolateral amygdala. The prefrontal cortex in turn sends
glutamatergic input back to the ventral tegmental area and to the nucleus
accumbens, an area that also receives glutamatergic input from the basolateral
amygdala and the hippocampus. This circuitry has been implicated as playing a
major role in reward-related learning, decision making, and memory. In addition,
glutamate is thought to modulate midbrain dopamine neurons, as stimulation of
glutamatergic afferents from the pedunculopontine tegmental nucleus increase
burst firing in A9 (substantia nigra) dopaminergic neurons (Lokwan, Overton, Berry,
& Clark, 1999). Within the midbrain, GABA afferents from striatonigral neurons
cause inhibition of dopamine neuron activity (Grace & Bunney, 1985). Furthermore,
when acute methamphetamine (0.15 mg/kg, i.v.) is administered to human subjects,
functional magnetic resonance indicates significant activation of the medial
orbitofrontal cortex, anterior cingulate cortex (rostral portion), and ventral striatum
(Vollm et al., 2004). The interactions of dopaminergic and glutamatergic signaling
are critical for reward-related learning and play a role in drug-induced neuronal
plasticity, in part due to the co-localization of receptors in medium spiny neurons of
the striatum (Berke & Hyman, 2000; Kelley, 2004; Smith & Bolam, 1990). While
dopamine signaling appears to be important for detecting unexpected
reinforcement, as well as motivation and incentive, the glutamatergic signal is
important for sensory/motor processing (Kelley, 2004).
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In addition to glutamate, a number of other neurotransmitters are known to
modulate mesocorticolimbic dopamine system, including acetylcholine.
Acetylcholine is the endogenous neurotransmitter that activates nicotinic and
muscarinic receptors. There are two major cholinergic systems in brain, one that
arises in the basal forebrain and projects to the cortex and hippocampus and
another that arises in the pedunculopontine tegmentum which sends ascending
projections to the thalamus and midbrain areas, including the substantia nigra and
ventral tegmental area (Dani & De Biasi, 2001). Importantly, activation of the
nicotinic receptors that are expressed on presynaptic dopamine neurons can lead to
increased neuronal firing in dopaminergic pathways (Dani & De Biasi, 2001).
Dopamine that is released from the presynaptic terminal into the synapse
diffuses and interacts with both pre and postsynaptic targets. The dopamine
receptors are classified as either D1 or D2-like and are G-protein coupled receptors.
D2 receptors function mainly as presynaptic autoreceptors. Stimulation these
receptors results in a decreased firing rate and diminished dopamine output from
the nerve terminal, while antagonism of the presynaptic D2 receptors results in
increased dopamine synthesis and release (Grace, 2002). Activation of D2
receptors results in the inhibition of adenylate cyclase, which subsequently reduces
the phosphorylation of cAMP-regulated phosphoprotein of 32,000kDa (DARPP-32;
Cooper et al., 2003). When DARPP-32 phosphorylation is reduced, the resulting
decrease in protein phosphatase 1inhibition leads to the dephosphorylation of
several proteins and ultimately inhibition of neurotransmitter release (Cooper et al.,
2003). The D1 receptors are primarily located on postsynaptic dendrites. Activation
of these receptors results in an increase in adenylate cyclase, which subsequently
increases the phosphorylation of DARPP-32 (Cooper et al., 2003). Increased
phosphorylation of DARPP-32 results in potent inhibition of protein phosphatase 1,
which interacts with intracellular signaling mechanisms thought to underlie synaptic
plasticity.
In addition, extracellular dopamine interacts with the dopamine transporter,
which functions normally as a reuptake mechanisms allowing dopamine to be taken
back into the presynaptic nerve terminal (Cooper, 2003). Once dopamine is taken
back into the presynaptic nerve terminal, it is sequestered in vesicular membranes
which protect it from oxidation by monoamine oxidase. The vesicular monoamine
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transporter is a protein located in the synaptic vesicular membrane and is
responsible for transporting dopamine into the vesicles. Within dopamine neuron
terminals, the vesicular monoamine transporter also plays an important role in
mediating dopamine release (Schuldiner, 1994).
Methamphetamine is a derivative of amphetamine and has a very similar
pharmacology (Melega, Williams, Schmitz, DiStefano, & Cho, 1995).
Amphetamines have several molecular targets including: 1) the dopamine
transporter; 2) monoamine oxidase activity; and 3) the vesicular monoamine
transporter (Mantle, Tipton, & Garrett, 1976; Seiden, Sabol, & Ricaurte, 1993).
Amphetamines enter the neuronal cytoplasm by diffusing across the bi-lipid layer
and acting as substrates for the dopamine transporter. Once inside, amphetamine
inhibits the vesicular monoamine transporter from sequestering dopamine into
vesicles and induces the reverse transport of cytosolic dopamine by the dopamine
transporter (Ary & Komiskey, 1980; Brown, Hanson, & Fleckenstein, 2000; Liang &
Rutledge, 1982; Philippu & Beyer, 1973; Sulzer et al., 1995). In addition to
inhibition of the vesicular monoamine transporter, methamphetamine enters the
vesicles which results in an altered pH gradient (“weak base” effect) that further
decreases the sequestration of neurotransmitter into vesicles (Sulzer et al., 1995).
Since amphetamine inhibits monoamine oxidase from metabolizing dopamine, the
increased amount of cytosolic dopamine available for amphetamine-induced
reverse transport results in an increase in extracellular dopamine and a decrease in
the dopamine metabolite DOPAC in the terminal and cell body regions of midbrain
dopamine neurons (Dwoskin & Crooks, 2002; Mantle et al., 1976).
A few differences between the neurochemical actions of amphetamine and
methamphetamine are emerging. For example, amphetamine has been shown to
be more effective than methamphetamine at increasing extracellular dopamine
concentrations in the PFC; however amphetamine and methamphetamine exhibit
similar efficacy at increasing extracellular dopamine concentrations in the nucleus
accumbens (Shoblock, Maisonneuve, & Glick, 2003). In addition, while the
norepinephrine transporter functions in concert with the dopamine transporter to
remove dopamine from the synapse following its release, amphetamine has a
higher binding affinity than methamphetamine for the norepinephrine transporter.
As a result, amphetamine is able to block the reuptake of and reversal of both the
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norepinephrine and the dopamine transporter, while methamphetamine blocks
primarily the dopamine transporter (Shoblock, Maisonneuve, & Glick, 2004).
Therefore, by acting through an additional mechanism, amphetamine administration
results in a greater concentration of extracellular dopamine in the mPFC than is
produced by methamphetamine.

Behavioral Aspects of Drug Dependence
Operant Conditioning
Individuals engage in many behaviors that have specific, reliable outcomes,
such as feeling satiated after eating; if the outcome resulting from a particular
behavior subsequently leads to an increase of that behavior, that outcome is said to
be reinforcing (Koob, 1992). Operant conditioning principles are used in animal
models to assess the reinforcing effects of drugs. Typically, animals are prepared
with an indwelling jugular catheter and trained to emit a response (i.e. pressing a
lever) in order to receive an infusion of a psychoactive drug. Most drugs that are
abused by humans are also self-administered by rodents (Gardner, 2000; Koob,
1992). This model allows for the preclinical assessment of interventions that will
potentially decrease drug-taking behavior. Behaviors that are reinforced, including
those that are biologically relevant, such as eating and engaging in sex, as well as
those that lead to the administration of psychoactive drugs, increase dopaminergic
neuronal activity in a number of structures and pathways (Kelley, 2004).
Both d and l-isomers of methamphetamine are self-administered by rats
(Pickens, 1967; Yokel & Pickens, 1973). The mesolimbic dopaminergic pathway is
critically involved in amphetamine self-administration, as dopamine agonists such
as apomorphine and piribedil decrease drug intake, whereas dopamine antagonists
such as (+)-butaclamol induce periods of increased drug intake (Yokel & Wise,
1976, 1978). This increase in responding likely reflects attenuation of the rewarding
effect of the drug, prompting the animal to increase operant responding to
compensate for the decreased drug effect. Lesions of the nucleus accumbens also
result in attenuation of amphetamine self-administration, further demonstrating a
critical role of this part of the circuitry in drug reward (Lyness, Friedle, & Moore,
1979).
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Pavlovian Conditioning
Pavlovian, or classical conditioning, is a form of associative learning that is
also important for aspects of drug dependence. In classical conditioning, a
temporal contingency is arranged between two stimuli such that one stimulus (the
conditioned stimulus) reliably predicts the occurrence of a second stimulus (the
unconditioned stimulus; Siegel, 1977). Prior to any pairings with the unconditioned
stimulus, the conditioned stimulus typically does not elicit a physiological response.
Presentation of the unconditioned stimulus alone will produce a physiological
response in an organism, which is known as the unconditioned response. However,
following repeated pairings of the conditioned stimulus with the unconditioned
stimulus, presentation of the conditioned stimulus alone will come to elicit a
physiological response known as the conditioned response. Pavlov (1927) was first
to demonstrate that a psychoactive drug is able to function as an unconditioned
stimulus. After repeatedly pairing the systemic effects of a psychoactive drug
(unconditioned stimulus) with a tone (conditioned stimulus), presentation of the tone
alone produced a physiological response similar to the drug action (Pavlov, 1927).
These principles can be used to understand the conditioned stimulus-reward
associations that are observed following repeated drug administration.
In humans, exposure to environmental stimuli that have become associated
with the psychoactive properties of a drug can, by themselves, elicit conditioned
responses that often lead to intense craving and relapse (O'Brien, Childress, &
McLellan, 1991; Stewart, 1992). When detoxified cocaine users were shown
videotapes of simulated cocaine use, they reported cocaine craving (Childress et
al., 1999). Concurrent positron emission tomography (PET) assessed in this study
indicated that subjects also displayed increased regional cerebral blood flow, an
indicator of increased neuronal activity, in limbic regions, including the amygdala
and anterior cingulate (Childress et al., 1999). Furthermore, when cocainedependent males were read a script of autobiographical drug-related events,
neuronal activation was observed in the amygdala, anterior cingulate, and nucleus
accumbens (Kilts et al., 2001). More recent studies have revealed that exposure to
conditioned stimuli in cocaine and amphetamine-dependent individuals results in
increased dopamine release in striatal regions (Boileau et al., 2007; Volkow et al.,
2006). These studies illustrate that conditioned cues cause neurophysiological
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changes in brain regions important for reward-related learning and the formation of
stimulus-reward associations.

Non-Associative Learning
While both operant and Pavlovian conditioning processes are important for
understanding drug addiction, non-associative mechanisms also play a role. It has
long been recognized that repeated administration of a psychostimulant induces an
enduring increase in locomotor activity and at least some of this change is due to
non-associative learning. Induction and expression of sensitization in an animal
model is thought to reflect changes that occur in the process of human drug
addiction (White & Kalivas, 1998). Thus, there has been a focused effort to fully
characterize the neurobiological mechanisms involved in learning and memory
because these mechanisms are thought to underlie the maladaptive behavioral
patterns associated with acquiring, ingesting, and craving psychoactive substances
(Kelley, 2004).

Conditioned Place Preference
Conditioned place preference (CPP) is an increasingly utilized paradigm that
is used to assess the rewarding properties of psychoactive drugs (for review Bardo
& Bevins, 2000; Tzschentke, 1998, 2007). Following repeated administration of a
psychoactive drug with a previously neutral environment, the cues associated with
that environment will take on secondary rewarding characteristics (i.e. the cues
become conditioned). Once this conditioning has occurred, exposure to the
conditioned cues results in approach behavior. This paradigm is well characterized
for many drugs of abuse and there are insights into the neuroanatomical regions
involved in this type of learning that have been derived from microinfusion and
lesioning studies (McBride, Murphy, & Ikemoto, 1999; Sellings & Clarke, 2003;
Tzschentke, 2007).
There are several variations in protocols used for CPP studies. Typically, a
three-compartment apparatus is used in which two larger end compartments are
connected with a smaller center compartment. All three compartments are distinct
(i.e. varying in color, floor texture, odor, etc.) and guillotine doors allow access to all
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three compartments or confinement to one of the end compartments. The three
phases that take place during a typical CPP experiment are: (1) preconditioning
test, (2) conditioning phase, and (3) postconditioning test. During the
preconditioning test, animals are allowed free access to all three compartments and
time spent in each is recorded. In an unbiased design, animals show no preference
for any of the experimental compartments during the preconditioning test as
measured by the time spent in each of the compartments. Animals are then
assigned randomly to an experimental group, and which end compartment will
serve as the “drug-paired” compartment is counterbalanced across all the animals.
In contrast, when animals show a preference for one of the end compartments
during the preconditioning test and the opposite end compartment (the nonpreferred side) serves as the “drug-paired” compartment during conditioning trials,
the design is said to be biased. The biased design is used less often as the
interpretation of the results derived from using this design is sometimes problematic
(Bardo & Bevins, 2000; Tzschentke, 2007).
Next, during the conditioning phase, animals undergo an experimental
manipulation prior to being confined to one of the end compartments during one
session and undergo a control session prior to being placed in the opposing end
compartment in a separate session. Typically, the experimental and control
manipulations are conducted on alternating days. Following completion of the
conditioning phase, animals undergo the postconditioning test where they are once
again allowed free access to the entire apparatus and time spent in each
compartment is assessed. If significantly more time is spent in the compartment
paired with the experimental manipulation than that paired with the control condition
or than the time spent in that compartment during the preconditioning test, that
manipulation induces a place preference. If significantly less time is spent in the
compartment paired with the experimental manipulation than that paired with the
control condition or than time spent in that compartment during the preconditioning
test, that manipulation induces a place aversion. Two separate aspects of CPP can
be assessed, acquisition and expression. During a test of acquisition, animals are
conditioned as described above and the animal undergoes the postconditioning test
in a drug-free state. Experimental manipulations in this type of design always occur
prior to or during the conditioning phase. Alternatively, during a test of expression
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animals are conditioned as described above and administered an experimental
manipulation (i.e. potential pharmacotherapy), prior to the postconditioning test.
There are several acceptable ways in which to report results from CPP
experiments using an unbiased design. The most straightforward method is to
compare the time spent (sec) in the previously drug-paired versus saline-paired
compartments. Alternatively, a difference score for each group can be calculated
by subtracting the time spent (sec) in the previously saline-paired compartment from
the time spent in the previously drug-paired compartment. This latter method
provides a single number for each experimental group which is advantageous when
assessing correlations between CPP data and another dependent variable, such as
locomotor activity. Another common approach is to calculate a preference ratio
using the following equation: (time spent in drug paired compartment) / (time spent
in drug + saline paired compartments). This ratio provides an index of preference
for the previously drug-paired compartment.
As with any preclinical model of reward/reinforcement, there are advantages
and disadvantages of the CPP paradigm, relative to the drug self-administration
paradigm, (Bardo & Bevins, 2000; Van der Kooy, 1987). The advantages of using
CPP include: (1) observation of either a preference or an aversion following an
experimental manipulation; (2) animals can be assessed for reward-related
behavior while in a drug-free state, ensuring that any behavior exhibited is not due
to drug-induced impairments; (3) given that animals do not typically have to undergo
surgical procedures and the experimental sessions are not as time consuming,
these experiments are more cost-efficient; and (4) two behaviors, locomotor activity
and reward, can be assessed simultaneously. There are several disadvantages as
well, including: (1) difficulty in obtaining a graded dose-effect curve; (2) when using
a biased design, it is difficult to determine if the testing apparatus is truly unbiased
across studies, making the results ambiguous; and (3) a CPP paradigm for human
subjects has not been developed. It appears that the neurocircuitry underlying the
classical conditioning processes that occur during CPP are distinct from those
underlying the instrumental learning that occurs during drug self-administration
(Bardo & Bevins, 2000).
Amphetamine, as well as methamphetamine, has been shown to induce
CPP. The acquisition of amphetamine CPP is blocked by both D1 and D2
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dopamine receptor antagonists, while only D1 receptor antagonism blocks the
expression of amphetamine CPP (Hoffman & Beninger, 1989; Liao, Chang, &
Wang, 1998; Spyraki, Fibiger, & Phillips, 1982). Amphetamine infused directly into
the nucleus accumbens results in CPP, an effect that is abolished by co-infusion of
a D1 antagonist into the nucleus accumbens, as well as by a 6-hydroxydopamine
lesion of the nucleus accumbens shell (Carr & White, 1983; Hiroi & White, 1991). In
addition to the nucleus accumbens, other brain regions in the limbic circuitry have
been implicated in amphetamine-induced CPP. Lesions of the cholinergic
pedunculopontine tegmental nucleus block the acquisition of amphetamine CPP,
while electrolytic lesions of the lateral nucleus of the amygdala block both
acquisition and expression of amphetamine CPP (Olmstead & Franklin, 1994).
Interestingly, while medial prefrontal cortex lesions block the acquisition of cocaine
CPP, these lesions have no effect on amphetamine CPP (Tzschentke, 1998).
Amphetamine CPP is also blocked by reserpine, a VMAT2 ligand that depletes
vesicular stores of dopamine (Hiroi & White, 1990). Thus, while acquisition and
expression of amphetamine CPP can be affected differentially, dopaminergic
neurotransmission in the nucleus accumbens plays a critical role for both.
Locomotor activity during the conditioning phase of CPP experiments is
reported frequently and it has been demonstrated that amphetamine-induced
locomotor stimulation is not necessary for its rewarding properties (Carr, Phillips, &
Fibiger, 1988). Amphetamine sensitization has been shown to be, at least in part,
dependent on contextual cues because the sensitized response is not observed if damphetamine is administered in a novel environment (Anagnostaras & Robinson,
1996). Many neurotransmitter systems have been implicated in the process of
sensitization, including dopamine, glutamate, and acetylcholine (White & Kalivas,
1998).
To what extent the outcomes of CPP, self-administration, and locomotor
activity experiments assessing psychostimulant-induced behaviors are correlated is
currently under debate. Sensitization is thought to occur during the acquisition of
psychostimulant self-administration (Schenk & Partridge, 1997). While
amphetamine-induced behaviors rely on the mesocorticolimbic dopamine pathway
and often occur simultaneously, they are dissociable.
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Lobeline as a Potential Pharmacotherapy for Methamphetamine Dependence
Recently, it has been postulated that lobeline, an active alkaloid found in
Indian tobacco (Lobelia inflata), may have potential as a pharmacotherapy for
psychostimulant abuse (Dwoskin & Crooks, 2002). Lobeline has a complex
pharmacological profile. This alkaloid has been classified historically as a nicotinic
receptor agonist that binds more selectively to high than to low affinity nicotinic
receptors in striatal preparations (Brioni, Decker, Sullivan, & Arneric, 1997; Decker,
Majchrzak, & Arneric, 1993). However, several lines of evidence now indicate that it
acts as a functional nicotinic receptor antagonist. In vitro studies have shown that
lobeline inhibits [3H]overflow from superfused [3H]dopamine-preloaded striatal slices
and acts as a functional antagonist as assessed in the rubidium efflux assay using
thalamic synaptosomes (D. K. Miller, Crooks, & Dwoskin, 2000; Teng, Crooks,
Sonsalla, & Dwoskin, 1997). In vivo microdialysis experiments in nicotine
pretreated rats (0.4 mg/kg, SC for 5 days) have demonstrated that systemic lobeline
administration does not change extracellular levels of dopamine or 3, 4dihydroxyphenylacetic acid (DOPAC) in the nucleus accumbens core (Benwell &
Balfour, 1998). Furthermore, repeated administration of nicotine results in
increased nicotinic receptor binding sites, whereas repeated administration of
lobeline does not alter the affinity or number of nicotinic receptor binding sites (Bhat,
Turner, Selvaag, Marks, & Collins, 1991). Consistent with the neurochemical
evidence that lobeline acts as a functional nicotinic receptor antagonist;
administration of lobeline specifically attenuates the locomotor-stimulating effects of
repeated nicotine administration (Miller et al., 2003). Thus, evidence from both
neurochemical and behavioral research strongly supports the view that lobeline is a
functional antagonist at neuronal nicotinic receptors in the mesolimbic dopamine
system.
In addition to the aforementioned activity at neuronal nicotinic receptors,
lobeline also interacts with the vesicular monoamine transporter to inhibit the
sequestration of dopamine into vesicular stores (Teng, Crooks, & Dwoskin, 1998).
It is thought that through this mechanism, lobeline has potential as a
pharmacotherapy for methamphetamine dependence (for review see (Dwoskin &
Crooks, 2002). Lobeline pretreatment selectively inhibits amphetamine induced
dopamine overflow in rat striatal slices as assessed in the endogenous dopamine
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release assay (Miller et al., 2001). These in vitro experiments have indicated that in
the presence of lobeline, presynaptic dopamine stores are redistributed, rendering
dopamine unavailable for methamphetamine-induced reverse transport (Dwoskin &
Crooks, 2002). It is likely that lobeline attenuates the rewarding properties of
methamphetamine through VMAT2 inhibition, although other mechanisms may also
play a role.
Lobeline may have potential as a pharmacotherapy for treating
methamphetamine dependence (Dwoskin & Crooks, 2002; Zheng, Dwoskin, &
Crooks, 2006). Using a rodent model of methamphetamine self-administration, the
potential of lobeline to decrease drug taking behavior was assessed (Harrod,
Dwoskin, Crooks, Klebaur, & Bardo, 2001). Male Sprague-Dawley rats were trained
to lever press for sucrose reinforcement, underwent surgery to implant an indwelling
jugular catheter, and were then trained to self-administer methamphetamine (0.05
mg/kg/infusion) on a terminal fixed ratio 5 schedule of reinforcement. A separate
group of rats was trained to lever press for sucrose reinforcement on a terminal
fixed ratio 5 schedule of reinforcement. Once stable responding was reached in
both assays, lobeline (0.3, 1.0 and 3.0 mg/kg, sc) pretreatments were administered.
The highest dose of lobeline (3 mg/kg) resulted in an acute decrease of both
methamphetamine infusions and sucrose pellets. Additional experiments
demonstrated that following 7 repeated administrations, lobeline (3 mg/kg)
selectively decreased methamphetamine infusions as tolerance developed to the
decrease in sucrose pellets earned (Harrod et al., 2001). Further, increasing the
unit dose of methamphetamine does not surmount the lobeline-induced decrease
(Harrod et al., 2001). While acute lobeline (3 mg/kg) administration prior to
methamphetamine (1.0 mg/kg) did not specifically decrease methamphetamineinduced reinstatement of methamphetamine-seeking behavior, an overall decrease
in number of responses was observed (Harrod, Dwoskin, Green, Gehrke, & Bardo,
2003). However, given that lobeline (3 mg/kg) has been shown to non-specifically
decrease operant behavior acutely, an effect that tolerates within four
administrations, it is unknown if repeated lobeline administration would result in
specific attenuation of methamphetamine-induced reinstatement of
methamphetamine-seeking behavior. It is also currently unknown if lobeline would
decrease cue-induced reinstatement of methamphetamine-seeking behavior. While
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there are currently no reports on human studies assessing lobeline’s efficacy as a
pharmacotherapy for methamphetamine dependence in a clinical population,
research from preclinical models appear promising.
Importantly, lobeline does not appear to have abuse liability. In one study,
four separate groups of male Sprague-Dawley rats were trained to lever press for
sucrose reinforcement, implanted with a jugular catheter, and allowed to selfadminister either saline or one dose of lobeline (0.015, 0.05, 0.15 mg/kg/infusion;
(Harrod et al., 2003). None of the rats acquired self-administration of lobeline at
any of the doses tested. In addition, acute lobeline (1 and 3 mg/kg) does not
reinstate extinguished methamphetamine-seeking behavior (Harrod et al., 2003).
Further, lobeline administration repeatedly paired with a distinct environment does
not induce a conditioned place preference (Fudala & Iwamoto, 1986). These
studies illustrate the utility of lobeline to inhibit reward-related behaviors induced by
psychostimulants without functioning as a reinforcer when administered alone.
As indicated previously, pharmacological manipulations can differentially
affect the acquisition and expression of CPP. While the effects of lobeline on
acquisition of methamphetamine CPP can provide insight into potential mechanisms
underlying the ability of lobeline to decrease methamphetamine reward, it is also
clinically relevant to determine if lobeline attenuates the expression of
methamphetamine CPP because a pharmacotherapy would be administered
following previous exposure to a psychoactive substance. Previous reports indicate
that administration of lobeline alone does not elicit drug-seeking behavior in rats
extinguished from methamphetamine-taking behavior (Harrod et al., 2003).
However, there is currently no available information of the effect of lobeline on cueinduced reinstatement of drug-seeking behavior.
Since methamphetamine CPP can be disrupted by a variety of
neuroanatomical and pharmacological manipulations, it is also of interest to assess
the neurochemical profile of lobeline administration prior to methamphetamine in
vivo. Currently, the proposed mechanisms by which lobeline is decreasing
methamphetamine reward are derived mostly from in vitro experiments. Given the
complexity of the limbic system pathways that are disrupted during tissue extraction,
it is essential that these effects are confirmed by in vivo experiments.
Copyright © Nichole Marie Neugebauer 2008

17

CHAPTER TWO
Experiment 1

Lobeline Attenuates the Acquisition of Methamphetamine-Induced
Conditioned Place Preference and Locomotor Activity.

The purpose of the first experiment was to assess if lobeline alters
methamphetamine CPP in rats. In contrast to self-administration, CPP is a model
that assesses the role of conditioned contextual cues in drug reward. In humans,
exposure to environmental or contextual cues that are associated with drugs of drug
through classical conditioning can elicit drug craving and relapse (O'Brien et al.,
1991). When tested in a drug-free state, re-exposure to amphetamine-associated
cues in healthy human volunteers increases dopaminergic transmission in the
ventral striatum similar to the increase observed following amphetamine
administration (IV) (Boileau et al., 2007; Drevets et al., 2001). Since lobeline has
been proposed to be a potential pharmacotherapy for methamphetamine
dependence, the ability of lobeline to disrupt the conditioned associations that are
formed by repeated pairings of methamphetamine with distinct contextual cues
warrants examination. In addition to assessing the effects of lobeline on
methamphetamine CPP, the current preclinical study also measured locomotor
activity during drug-conditioning trials. It was hypothesized that lobeline would
attenuate methamphetamine-induced hyperactivity and inhibit the acquisition of
methamphetamine-induced CPP.

Methods
Subjects
Male Sprague-Dawley rats (N=110, 225-250 g; Harlan Industries,
Indianapolis, IN) were housed two per cage, with ad libitum access to food and
water. The colony room was maintained on a 12-hr/12-hr light/dark cycle and
controlled for temperature and humidity. All animals were handled at least 5 min on
each of the 3 days prior to commencement of the experiment. Experiments were
conducted during the light phase. All experimental protocols were conducted in
strict accordance with the National Institutes of Health Guide for the Care and Use
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of Laboratory Animals and were approved by the Institutional Animal Care and Use
Committee at the University of Kentucky.

Drugs
Methamphetamine hydrochloride was obtained from the National Institute on
Drug Abuse (Research Triangle Park, NC, USA). Lobeline hemisulfate was
purchased from ICN (Costa Mesa, CA). Doses of methamphetamine and lobeline
were calculated as salt weight, were dissolved in 0.9% NaCl (saline) and were
administered in 1 ml/kg volume. Lobeline was administered via SC injection and
methamphetamine was administered via IP injection.

Apparatus
CPP and locomotor activity were assessed using an automated, 3compartment apparatus operated via a computer interface equipped with MED-PC
IV software (ENV-013; Med Associates, St. Albans, VT). The apparatus was 68 x 21
x 21 cm and consisted of three distinct compartments: two 28-cm long side
compartments (one colored black with a stainless steel rod floor and one colored
white with a stainless steel mesh floor) separated by a 12-cm long central gray
compartment with a smooth PVC floor. Guillotine doors separated each side
chamber from the central chamber and were manipulated in order to confine rats to
one of the side compartments or to allow free access to all three compartments.
Inside each side compartment, six photobeams were located 1.25 cm from the end
wall and 5 cm apart. Inside the central gray compartment, there were three
photobeams spaced 4.75 cm apart.

Experimental Procedure
Twelve separate groups of animals (n=8-11) were used in the current study,
making up a 3 x 4 (lobeline dose x methamphetamine dose) experimental design.
On Day 1 (preconditioning test), animals were placed individually in the apparatus
with both guillotine doors open to allow access to the entire apparatus for 15 min to
determine the initial preference. On Days 2-9 (conditioning sessions), animals were
confined to each side of the apparatus on alternating days. On drug conditioning
days, animals were pretreated with saline or lobeline (1 or 3 mg/kg, SC) and were
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placed back into their home cage for 15 min. Animals were then injected with saline
or methamphetamine (0.5, 1 or 3 mg/kg, IP) and placed immediately in one of the
side compartments (white or black; counterbalanced within treatment group
regardless of initial preference) for 30 min. Locomotor activity was recorded as the
number of beam breaks on the last drug conditioning trial. On the alternating days,
animals were treated similarly except that both injections were saline and the
animals were placed into the opposite side compartment. On Day 10
(postconditioning test), preference was assessed by placing the animal in the center
grey compartment with free access to all compartments for 15 min. The amount of
time spent in each compartment was recorded and CPP was defined as a
significant increase in time spent in the drug-paired compartment relative to the
saline-paired compartment.

Data Analysis
Locomotor activity was assessed by analyzing the number of horizontal
beam breaks during the last drug-conditioning session using a one-way ANOVA
across treatment groups. Posthoc analyses were conducted using unpaired t-tests
(one-tailed) with correction for family-wise error to determine significant between
group differences. Significance level for all analyses was set at p<0.05. Preference
data were analyzed as time (sec) spent in the saline versus drug-paired
compartments during the postconditioning test session using a 12 x 2 (treatment
groups x compartment) mixed factor analysis of variance (ANOVA), with treatment
groups as a between-subject factor and compartment as a within-subject, repeated
measure factor. Posthoc analyses were conducted using paired t-tests (one-tailed)
with correction for family-wise error to assess differences in time spent in saline
versus drug-paired compartments within each group.

Results
Locomotor Activity
The overall analysis of locomotor activity during the last drug conditioning
session revealed a significant main effect of treatment group (F(11,98)=3.185;
p<0.001). Figure 2.1 illustrates that all methamphetamine (0.5, 1.5 and 3 mg/kg)
conditioning groups showed a significant increase in locomotor activity compared to
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saline control (panel A), while no difference was observed between the saline
control and either lobeline (1 and 3 mg/kg) alone groups (panel B).
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Figure 2.1 Locomotor Activity During the 4th Drug Conditioning Session
for Control Groups. Mean (± SEM) horizontal beam breaks in the drug-paired
compartment during the last drug conditioning session (Trial 4) following
methamphetamine (0, 0.5, 1 or 3 mg/kg) alone (Panel A) or lobeline (0, 1 or 3
mg/kg) alone (Panel B). Asterisk (*) indicates a significant difference from SALSAL group; p<0.05.

Figure 2.2 illustrates that lobeline (1 and 3 mg/kg) pretreatment did not alter
locomotor activity following the lower methamphetamine doses (0.5 mg/kg; panel A
or 1.5 mg/kg; panel B) on the last conditioning session. In addition, the lower dose
of lobeline (1 mg/kg) did not significantly alter the effect of 3 mg/kg of
methamphetamine (Figure 2.2, panel C). However, 3 mg/kg of lobeline significantly
attenuated locomotor activity following the highest dose of methamphetamine (3
mg/kg).
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Figure 2.2 Locomotor Activity During the 4th Drug Conditioning Session
For Lobeline-Methamphetamine Groups. Mean (± SEM) beam breaks in the
drug-paired compartment during the last drug conditioning session (Trial 4)
following pretreatment with lobeline (0, 1 or 3 mg/kg) prior to methamphetamine (0,
0.5, 1 or 3 mg/kg). The dashed line represents the number of beam breaks in the
SAL-SAL group. Panel A: Lobeline (0, 1 or 3 mg/kg) pretreatment combined with
methamphetamine (0.5 mg/kg). Panel B: Lobeline (0, 1 or 3 mg/kg) pretreatment
combined with methamphetamine (1.5 mg/kg). Panel C: Lobeline (0, 1 or 3 mg/kg)
pretreatment combine with methamphetamine (3 mg/kg). Asterisk (*) indicates a
significant difference from SAL-SAL group, which is represented by the dashed line;
p<0.05. Hatch (#) indicates a significant difference from SAL-METH 3; p<0.05.

Acquisition of Conditioned Place Preference
The overall analysis of time spent in each compartment during the
postconditioning test revealed significant main effects of treatment group
(F(11,98)=8.06; p<0.01) and compartment (saline or drug-paired; F(1,98)=70.92;
p<0.01). In addition, ANOVA indicated that there was a significant interaction of
compartment (saline or drug-paired) x treatment group (F(11,98)=3.71; p<0.01).
Significant CPP was observed with each methamphetamine conditioning dose (0.5,
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1.5 and 3 mg/kg; Fig 2.3A), while lobeline alone did not alter preference significantly
(Fig 2.3B). In addition, control rats conditioned with saline alone did not show a
preference for either compartment during the postconditioning test.
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Figure 2.3 Acquisition of CPP for Control Groups. Mean (± SEM) amount of
time rats spent in the saline- and drug-paired compartments during the 15 min
postconditioning test following methamphetamine (0, 0.5, 1 or 3 mg/kg; Panel A) or
lobeline (0, 1 or 3 mg/kg; Panel B) alone. Asterisk (*) indicates a significant withinsubject difference in time spent in the saline versus drug paired compartment;
p<0.05.
During conditioning with the lowest dose of methamphetamine (0.5 mg/kg),
pretreatment with either dose of lobeline (1 or 3 mg/kg) blocked the acquisition of
methamphetamine-induced CPP (Figure 2.4 A). However, during conditioning with
the higher methamphetamine doses (1.5 or 3 mg/kg), pretreatment with either dose
of lobeline (1 or 3 mg/kg) during conditioning had no significant effect on the
acquisition of methamphetamine-induced CPP (Figure 2.4B and 2.4C), as rats
spent more time in the previously drug-paired compartment during the
postconditioning test.

23

0

0

Conditioning Group

L
SA
SA
L-

1.
5
H
ET
3M

B
LO

B

1M

ET

H

1.
5

1.
5

L
LSA

LM
ET
H
SA

Conditioning Group

ET
H

50

3

50

M

100

3

150

100

3-

0.
5
ET

LO

B

3M

ET
1M
B
LO

200

H

0.
5
H

H
ET
LM
SA

SA

LS

A

L

0.
5

0

150

250

B

50

200

300

ET
H

100

250

350

M

150

300

400

LO

200

350

*

*

450

3

250

400

*

500

1-

300

*

450

B

350

SALINE
DRUG

LO

Time Spent in Compartment (sec)

400

600
550

*

500

*

450

C

*

M
ET
H

SALINE
DRUG

550

500
Time Spent in Compartment (sec)

600

SA
L-

B

Time Spent in Compartment (sec)

SALINE
DRUG

550

LO

600

SA

A

Conditioning Group

Figure 2.4 Acquisition of CPP in Lobeline-Methamphetamine Groups. Mean
(± SEM) amount of time spent in the saline- and drug-paired compartments during
the 15-min postconditioning test for the groups pretreated with lobeline (0, 1 or 3
mg/kg) prior to methamphetamine (0, 0.5, 1 or 3 mg/kg) during the conditioning
phase. Panel A: lobeline (0, 1 or 3 mg/kg) pretreatment combined with
methamphetamine (0.5 mg/kg). Panel B: Lobeline (0, 1 or 3 mg/kg) pretreatment
combined with methamphetamine (1.5 mg/kg). Panel C: Lobeline (0, 1 or 3 mg/kg)
pretreatment combined with methamphetamine (3 mg/kg). Asterisk (*) indicates a
significant within-subject difference in time spent in the saline versus drug paired
compartment; p<0.05.

Summary of Experiment 1
The aim of the current experiment was to examine the effect of lobeline on
methamphetamine-induce locomotor hyperactivity and acquisition of CPP. During
the last drug conditioning session, rats were confined to one end compartment and
horizontal beam breaks were recorded for the 30 min session. Methamphetamine
(0.5, 1.5 and 3 mg/kg) dose dependently induced hyperactivity during the last
conditioning session compared to the saline control group, while lobeline (1 or 3
mg/kg) alone did not alter locomotor activity during this session. Previous research
suggests that acute lobeline (3 mg/kg) induces non-specific hypoactivity in rats
(Harrod et al., 2001; Miller et al., 2001). Lobeline (3 mg/kg) did significantly

24

attenuate locomotor activity during the first conditioning session in the current study
(data not shown). However, tolerance to the hypoactivity was evident within four
administrations, as no hypoactivity was evident on the last conditioning session.
The lower dose of lobeline (1.0 mg/kg) did not block methamphetamine (0.5, 1.5 or
3.0)-induced hyperactivity. Interestingly, the higher dose of lobeline (3.0 mg/kg)
attenuated locomotor hyperactivity only in combination with the highest
methamphetamine (3.0 mg/kg) dose administered. When the methamphetamine
dose is increased from 1.5 to 3 mg/kg, additional pharmacological consequences
may be induced that contribute to the increase in methamphetamine-induced
hyperactivity. Lobeline may be interfering with these additional pharmacological
mechanisms, resulting in a decrease in methamphetamine-induced locomotor
activity.
All rats receiving methamphetamine during the conditioning phase acquired
CPP. Importantly, neither dose of lobeline (1 or 3 mg/kg) induced CPP or place
aversion, which is congruent with previous findings (Fudala & Iwamoto, 1986). As
hypothesized, lobeline (1 and 3 mg/kg) administration prior to methamphetamine
(0.5 mg/kg) during the conditioning phase blocked the acquisition of CPP.
However, the lobeline-induced blockade was surmounted when rats were
conditioned with higher doses of methamphetamine (1.5 and 3.0 mg/kg).
Interestingly, previous research from our laboratory has indicated that the ability of
lobeline to decrease methamphetamine self-administration is not surmounted by
increasing the unit dose of methamphetamine (Harrod et al., 2001). This
discrepancy in results obtained from self-administration and CPP paradigms is not
unique as previous research has demonstrated that pharmacological manipulations
can differentially affect these paradigms (Bardo & Bevins, 2000). The current
results demonstrate that lobeline (1 and 3 mg/kg) can decrease the acquisition of
CPP induced by a low dose of methamphetamine (0.5 mg/kg). In addition, the
lobeline (3 mg/kg)-induced attenuation of methamphetamine (3 mg/kg)-induced
hyperactivity was not correlated with a decrease in the rewarding properties of
methamphetamine, demonstrating that these two behavioral effects are dissociable.

Copyright © Nichole Marie Neugebauer 2008
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CHAPTER THREE
Experiment 2

Lobeline Attenuates the Expression of Methamphetamine-Induced
Conditioned Place Preference
In order to determine if lobeline attenuates the expression of an established
methamphetamine CPP, lobeline was administered prior to postconditioning tests.
As discussed in the introduction, the neurochemical mechanisms involved in the
acquisition of methamphetamine CPP are dissociable from those involved in the
expression of methamphetamine CPP. This is clinically relevant because
methamphetamine-induced cellular adaptations and learned associations are
generally formed prior to an individual seeking treatment for dependence. The
expression of CPP in rodents is thought to model context-conditioned reward in
humans. Although no parallel experimental paradigm has been established in
humans, it is well recognized that exposure to contextual cues that have been
associated previously with drug effects often elicit drug craving. It has been
previously reported that lobeline does not specifically attenuate methamphetamineinduced reinstatement of lever responding in rats following extinction of
methamphetamine self-administration (Harrod et al., 2003). As such, it was
hypothesized that lobeline would not specifically inhibit the expression of
methamphetamine-induced CPP.

Methods
Subjects
One hundred and four male Sprague-Dawley rats (n=10-12/group; 225-250
g; Harlan Industries, Indianapolis, IN) were used in the current study. These rats
were treated identically to those described in experiment 1.

Drugs
Same as described in Experiment 1.

Apparatus
Same as described in Experiment 1.
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Experimental Procedure
Nine separate groups of animals were assigned randomly to one of nine
different treatment groups, making up a 3 x 3 factorial design (Table 1).

Table 3.1 Experimental groups for Experiment 2.
Drug Conditioning
SAL
SAL
SAL
METH 0.5 mg/kg
METH 0.5 mg/kg
METH 0.5 mg/kg
METH 1.5 mg/kg
METH 1.5 mg/kg
METH 1.5 mg/kg

Postconditioning Test
SAL
LOB 1 mg/kg
LOB 3 mg/kg
SAL
LOB 1 mg/kg
LOB 3 mg/kg
SAL
LOB 1 mg/kg
LOB 3 mg/kg

n
10
10
12
12
12
12
12
12
12

On Day 1 (preconditioning test), animals were placed in the apparatus with
both guillotine doors open to allow access to the entire apparatus during which their
initial place preference during a 15-min session was determined. On Days 2-9
(conditioning phase), animals were confined to one of the end compartments and
underwent saline or drug conditioning trials on alternating days. On drug
conditioning trials, animals were administered saline or methamphetamine (0.5 or
1.5 mg/kg, IP) and immediately placed in one of the end compartments in a
counterbalanced manner (white or black; drug paired compartment) for 30 min.
These doses of methamphetamine were chosen based on previously published
results and based on preliminary experiments from our laboratory indicating that 0.5
mg/kg of methamphetamine is the minimal dose that will result in reliable
conditioned place preference (Kuo et al., 2007). On alternate days, animals were
injected with saline (IP) and placed in the opposite end chamber (saline paired
compartment). On Days 10-11 (postconditioning tests), saline or lobeline (1 or 3
mg/kg, SC) was administered in a counter balanced manner and 15 min later
methamphetamine-induced conditioned place preference was assessed by placing
the animal in the grey (center) compartment with free access to all compartments
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for 15 min. These postconditioning tests are referred to as the 1st saline and 1st
lobeline post-tests. On Days 12-15, each rat was administered saline or their
respective dose of lobeline for 4 consecutive days and tested in an identical
procedure described for the previous postconditioning test in order to assess the
effects of repeated lobeline. Days 12-15 are referred to as the 2nd to 5th lobeline
post-tests. On Day 16, all animals received saline prior to a postconditioning test in
order to assess the persistence of the methamphetamine-induced CPP. Day 16 is
referred to as the final saline post-test.

Data Analysis
All data are expressed as group means ± SEM. Initially, horizontal beam
breaks in each of the compartments were recorded during each postconditioning
test and a rate of locomotor activity was calculated using the following equation:
horizontal beam breaks / time spent in compartment. These data were analyzed
using a mixed factor ANOVA with group as a between-subject variable and
compartment and postconditioning test day as within-subject variables. This
analysis indicated no differences in the rate of locomotor activity between the two
end compartments so the beam breaks were collapsed in all subsequent analyses.
Locomotor activity data are expressed as the total number of horizontal beam
breaks in all 3 compartments during each of the postconditioning tests as and were
analyzed using a mixed factor ANOVA, with group as a between-subject variable
and postconditioning test day as a within-subject variable. Post-hoc analyses were
conducted using paired and unpaired t-tests (one-tailed) with correction for familywise error to determine significant group differences. CPP data were analyzed as
time (sec) spent in the saline versus methamphetamine-paired compartments
during the postconditioning-test using an overall 3-way mixed factor ANOVA, with
group as a between-subject variable and compartment and postconditioning test
day as within-subject variables. Subsequent 3-way ANOVAs were conducted for
each conditioning group. Post-hoc analyses were conducted using paired t-tests
(one-tailed) with correction for family-wise error to determine significant decreases
in time spent in the saline versus drug-paired compartments within each
conditioning group. In order to assess whether the non-specific hypoactivity
typically induced by lobeline confounds the expression of CPP, correlational
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analyses were conducted. For these analyses, a difference score was calculated
for CPP using the following equation: time spent in drug – time spent in saline.
Separate Pearson’s correlations were conducted using the CPP difference score
and total horizontal beam breaks on each of the postconditioning test sessions.
Significance level (alpha) for all analyses was set at p<0.05.

Results
Locomotor Activity During Postconditioning Tests
The overall 2-way ANOVA of locomotor activity across postconditioning tests
indicated significant main effects of treatment group (F(8,92)=3.69; p<0.01) and
postconditioning test (F(3,24)=37.18; p<0.01). An interaction of treatment group x
postconditioning test was also revealed (F(24,276)=8.07; p<0.01). Three separate
groups of animals were administered saline during the conditioning phase of the
experiment and underwent repeated postconditioning test sessions (Figure 3.1).
Within the group that was repeatedly challenged with saline during these
postconditioning tests, a decrease in activity was observed by the 5th repeated
postconditioning test (p<0.05). Interestingly, no decrease was observed in rats
repeatedly challenged with the lower dose of lobeline (1 mg/kg), indicating an effect
indicative of habituation. Administration of the higher dose of lobeline (3 mg/kg)
resulted in acute and persistent suppression of locomotor activity (p<0.05).
However, some tolerance to the suppressant effect was observed between the 1st
and 5th lobeline administration (p<0.05). No significant decrease was observed
between the 1st and final saline challenge sessions, indicating no enduring
suppressant effect of lobeline.
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Saline Conditioned Groups
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Figure 3.1 Locomotor Activity During Postconditioning Tests in Rats
that Received Saline During the Conditioning Phase. Mean (± SEM) horizontal
beam breaks in the CPP apparatus following lobeline (0, 1 or 3 mg/kg) pretreatment
during the 15-min postconditioning test session. All rats received saline during the
conditioning phase. Asterisk (*) indicates a significant difference between bars
(p<0.05).

Three separate groups of animals were administered a low dose of
methamphetamine (0.5 mg/kg) during the conditioning phase of the experiment and
underwent repeated postconditioning test sessions (Figure 3.2). Rats repeatedly
challenged with saline showed no differences across postconditioning test sessions
(p<0.05). However, a significant decrease was observed following repeated testing
with the lower dose of lobeline (1 mg/kg). The higher dose of lobeline (3 mg/kg)
resulted in acute and persistent suppression of locomotor activity (p<0.05).
However, some tolerance to this suppressant effect was observed between the 1 st
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and 5th lobeline administration (p<0.05). A significant decrease was also observed
between the 1st and final saline challenge sessions.

METH 0.5 mg/kg Conditioned Groups
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Figure 3.2 Locomotor Activity During Postconditioning Tests in Rats that
Received Methamphetamine (0.5 mg/kg) During the Conditioning Phase.
Mean (± SEM) horizontal beam breaks in the CPP apparatus following lobeline (0, 1
or 3 mg/kg) pretreatment during the 15-min postconditioning test session. All rats
received methamphetamine (0.5 mg/kg) during the conditioning phase. Asterisk (*)
indicates a significant difference between bars (p<0.05).

Three separate groups of animals were administered a high dose of
methamphetamine (1.5 mg/kg) during the conditioning phase of the experiment and
underwent repeated postconditioning test sessions (Figure 3.3). Rats repeatedly
challenged with saline across postconditioning tests showed a significant decrease
by the final saline postconditioning test, suggestive of habituation to the test
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chamber (Figure 3.6; p<0.05). A decrease was also observed between the 1st
saline and last saline postconditioning test sessions in rats repeatedly challenged
with the lower dose of lobeline (1 mg/kg). Administration of the higher dose of
lobeline (3 mg/kg) resulted in acute and persistent suppression of locomotor activity
(p<0.05). However, some tolerance to this suppressant effect was observed
between the 1st and 5th lobeline administration (p<0.05). A significant decrease was
also observed between the 1st and final saline challenge sessions.
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Figure 3.3 Locomotor Activity During Postconditioning Tests in Rats that
Received Methamphetamine (1.5 mg/kg) During the Conditioning Phase.
Mean (± SEM) horizontal beam breaks in the CPP apparatus following lobeline (0, 1
or 3 mg/kg) pretreatment during the 15-min postconditioning test session. All rats
received methamphetamine (1.5 mg/kg) during the conditioning phase. Asterisk (*)
indicates a significant difference between bars (p<0.05).
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Expression of Conditioned Place Preference
The overall analysis of time spent in the saline versus drug paired
compartments across 7 consecutive postconditioning test days indicated significant
main effects of test day (F(3,276)=3.07; p<0.05) and compartment (F(1,92)=25.32;
p<0.01). In addition, a significant compartment x group interaction (F(8,276)=2.01;
p<0.05) was revealed. Separate 3-way ANOVAs were conducted for each of the 3
conditioning groups (0, 0.5 and 1.5 mg/kg). There were no significant differences
found in the saline conditioned groups (Figure 3.4 Panels A-D).
Saline Conditioned Groups
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Figure 3.4 Expression of CPP in Rats that Received Saline During the
Conditioning Phase. Mean (± SEM) amount of time spent in the saline- and drugpaired compartments in the saline conditioned control group pretreated with lobeline
(0, 1 or 3 mg/kg) 15 min prior to 15-min postconditioning test sessions. Panel A-D:
No group exhibited CPP during any of the postconditioning test sessions.

However, in the methamphetamine (0.5 mg/kg) conditioned groups (Figure
3.5) the analysis revealed a main effect of compartment (F(1,33)=21.33; p<0.01).
Planned comparisons that revealed all groups conditioned with methamphetamine
(0.5 mg/kg) spent significantly more time in the drug paired compartment on the 1st
saline and final saline postconditioning tests, indicating a persistent
methamphetamine-induced CPP across the repeated test days. The lower dose of
lobeline (1 mg/kg) did not attenuate this response on the 1st lobeline
postconditioning test. Interestingly, repeated administration of this dose did
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attenuate the expression of CPP on the 5th lobeline postconditioning test (p<0.05).
The higher dose of lobeline (3 mg/kg) attenuated the expression of CPP on both the
1st and 5th lobeline postconditioning tests (p<0.05).
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Figure 3.5 Expression of CPP in Rats that Received Methamphetamine
(0.5 mg/kg) During the Conditioning Phase. Mean (± SEM) amount of time spent
in the saline- and drug-paired compartments in treatment groups conditioned with
methamphetamine (0.5 mg/kg) and pretreated with lobeline (0, 1 or 3 mg/kg) 15 min
prior to 15-min postconditioning test sessions. Panel A: All treatment groups
showed significant acquisition of methamphetamine CPP. Panel B: Acute lobeline
(3 mg/kg) pretreatment blocked the expression of methamphetamine (0.5 mg/kg)induced CPP. Panel C: Repeated lobeline (1 or 3 mg/kg) pretreatment blocked the
expression of methamphetamine (0.5 mg/kg)-induced CPP. Panel D: All treatment
groups showed persistent expression of methamphetamine CPP on the final saline
challenge day. Asterisk (*) indicates a significant difference in time spent in the
saline versus drug paired compartment; p<0.05.

In the methamphetamine (1.5 mg/kg) conditioned groups (Figure 3.6), the
analysis revealed a main effect of compartment (F(1,32)=18.20; p<0.01), as well as
an interaction of compartment x test day (F(3,96)=2.80; p<0.05). Planned
comparisons revealed that rats conditioned with methamphetamine (1.5 mg/kg) and
given a saline injection on the 1st and final saline postconditioning tests showed
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significant CPP, indicating a persistent methamphetamine-induced CPP across test
days. The lower dose of lobeline (1 mg/kg) did not attenuate this response on the
1st lobeline postconditioning test, but repeated administration of this dose did
attenuate the expression of CPP on the 5th postconditioning test (p<0.05).
However, the higher dose of lobeline (3 mg/kg) attenuated the expression of CPP
on both the 1st and 5th lobeline postconditioning tests (p<0.05). In addition, the
lobeline (1 and 3 mg/kg) pretreatment groups did not show significant conditioned
place preference on the final saline postconditioning test.
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Figure 3.6 Expression of CPP in Rats that Received Methamphetamine
(1.5 mg/kg) During the Conditioning Phase. Mean (± SEM) amount of time spent
in the saline- and drug-paired compartments in treatment groups conditioned with
methamphetamine (1.5 mg/kg) and pretreated with lobeline (0, 1 or 3 mg/kg) 15 min
prior to 15-min postconditioning test sessions. Panel A: All treatment groups
showed significant acquisition of methamphetamine CPP. Panel B: Acute lobeline
(3 mg/kg) pretreatment blocked the expression of methamphetamine (0.5 mg/kg)induced CPP. Panel C: Repeated lobeline (1 or 3 mg/kg) pretreatment blocked the
expression of methamphetamine (0.5 mg/kg)-induced CPP. Panel D: Repeated
lobeline (1 or 3 mg/kg) pretreatment resulted in extinction of CPP on the final saline
postconditioning test. Asterisk (*) indicates a significant difference in time spent in
the saline versus drug paired compartment; p<0.05.
No significant correlation was found between locomotor activity and
expression of CPP when all conditioning groups were included on the 1st SAL (r =
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.15, n=101, n.s.), 1st LOB (r = .09, n=101, n.s.), 5th LOB (r = .19, n=101, n.s.) or
Final SAL (r = .04, n=101, n.s.) postconditioning tests. Correlations conducted on
each of the experimental groups at each postconditioning test day indicated no
correlation existed between locomotor activity and expression of CPP.

Summary of Experiment 2
The aim of the current experiment was extend the findings presented in
Experiment 1 by assessing the effects of lobeline on expression of
methamphetamine-induced CPP. During the repeated postconditioning sessions,
rats were administered saline or lobeline (1 or 3 mg/kg) 15 min prior to being placed
in the CPP apparatus where they had access to all 3 compartments. Horizontal
beam breaks were recorded for the 15 min test session. No differences between
conditioning groups were observed on the first saline postconditioning test,
indicating no conditioned hyperactivity in the methamphetamine conditioned groups.
Regardless of conditioning group, significant decreases in locomotor activity were
observed across the postconditioning sessions in rats that received saline or
lobeline (1 mg/kg). However, these differences were small and likely due to
habituation to the testing apparatus. Interestingly, lobeline (3 mg/kg) induced
hypoactivity across all conditioning groups. While tolerance to this hypoactivity was
evident following 5 repeated administrations, significant hypoactivity compared to
saline was still observed. The expression of CPP was not correlated with locomotor
activity, indicating that the expression of CPP is not likely masked by locomotor
suppression.
In rats conditioned with the lower dose of methamphetamine (0.5 mg/kg), all
groups spent significantly more time in the previously drug versus saline-paired
compartment on the first saline postconditioning test, indicating significant
acquisition of CPP. Moreover, the methamphetamine (0.5 mg/kg) conditioned
groups, regardless of postconditioning test pretreatment, maintained significant
CPP across postconditioning tests, demonstrating the persistence of CPP across
the experimental regimen. Acute administration of the lower dose of lobeline (1
mg/kg) did not attenuate the expression of CPP (1st LOB Post-Test). However, by
the 5th lobeline administration, a significant attenuation was observed, indicating
differences in acute and repeated effects of this lower dose of lobeline. In addition,
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acute and repeated administration of the higher dose of lobeline (3 mg/kg) resulted
in a persistent blockade in expression of CPP.
Following conditioning with the higher dose of methamphetamine (1.5
mg/kg), all groups showed significant acquisition of CPP. In contrast to the
methamphetamine (0.5 mg/kg) conditioned groups, the methamphetamine (1.5
mg/kg) conditioned groups showed less persistent CPP. In rats that received
saline across all postconditioning tests, significant expression of CPP on the 5th
lobeline postconditioning test was not observed. It is not clear why significant CPP
was not observed on this day, but was again evident on the final saline
postconditioning test. In addition, neither lobeline (1 or 3 mg/kg) pretreatment group
demonstrated significant CPP on the final saline postconditioning test. Similar to
the effects observed in the methamphetamine (0.5 mg/kg)-conditioned group, acute
administration of the lower dose of lobeline (1 mg/kg) had effect no on the
expression of CPP, but attenuation was evident following repeated administration.
In addition, this group did not show persistent CPP on the final saline
postconditioning test. Acute and repeated administration of the higher dose of
lobeline (3 mg/kg) blocked expression of CPP and suppressed locomotor activity on
the 1st and 5th lobeline administration. However, this group did not show significant
CPP on the final saline postconditioning test. Contrary to the hypothesis, these
results demonstrate that repeated administration of lobeline decreases expression
of methamphetamine-induced CPP. It is not clear why the expression of CPP was
persistent across repeated postconditioning tests when a low dose of
methamphetamine (0.5 mg/kg) was, but not when a high dose (1.5 mg/kg) was
used. It is unlikely that the absence of CPP in the methamphetamine (1.5 mg/kg)
conditioned groups that received repeated lobeline is due to non-specific extinction
of CPP as groups pretreated with saline during the repeated postconditioning-tests
continued to display significant CPP on the final test day. In addition, previous work
has shown that methamphetamine CPP is resistant to extinction when rats are
given repeated postconditioning tests for 10 consecutive days (Bahi, Kusnecov, &
Dreyer, 2008).

Copyright © Nichole Marie Neugebauer 2008
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CHAPTER FOUR
Experiment 3

Lobeline Alters Methamphetamine-Induced Changes in the Nucleus
Accumbens Shell

The nucleus accumbens shell is a neuroanatomical area that has been
implicated in playing a vital role in mediating the reinforcing effects of
psychostimulants. Dopaminergic mechanisms in this brain region have been shown
to be particularly important in the circuitry underlying drug-taking behaviors. Since
lobeline has been shown to attenuate behaviors associated with the reinforcing and
rewarding aspects of methamphetamine, it is of interest to assess the effects of
lobeline on extracellular dopamine in this brain region. In addition, the mechanism
by which lobeline disrupts methamphetamine-induced alterations in dopamine
release has been assessed solely at the in vitro level, so determining if this
neurochemical effect is also observed in vivo using microdialysis in an awake and
behaving animal is warranted. Additionally, extracellular levels of DOPAC were
assessed to determine if systemic lobeline administration results in an increased
level of extracellular DOPAC, as lobeline is thought to increase the amount of
cytosolic dopamine available for metabolism (Dwoskin & Crooks, 2002). It was
hypothesized that lobeline would attenuate methamphetamine-induced alterations
in extracellular dopamine and DOPAC in the nucleus accumbens shell.

Methods
Subjects
Male Sprague-Dawley rats (N=32; 225-250 g) were obtained from Harlan
Industries (Indianapolis, IN) and housed one per cage. In all other respects, rats
were cared for as described in Experiment 1.

Drugs and Chemicals
Ketamine (80 mg/kg, IP) and diazepam (5 mg/kg, IP) were be used as
anesthetics during surgical procedures. All other drugs were the same as described
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in Experiment 1. All reagents for the aCSF, HPLC mobile phase were obtained
from Sigma (St. Louis, MO).

Surgery
Animals were anesthetized and implanted with guide cannula (secured with
dental acrylic) aimed at the nucleus accumbens using the following coordinates
relative to bregma: AP +1.6 mm, L +0.8 mm, and D/V -5.8 mm (Paxinos & Watson,
1986). Guide cannula (20 gauge; MD-2251) and probes (2mm; MD-2200) were
obtained from BAS (Indianapolis, Indiana).

In Vivo Microdialysis
Microdialysis experiments were conducted using a swivel system (BAS)
attached to the side of a Plexiglass chamber (25 x 44 x 38 cm), which contained
pine chip bedding. Rats were assigned randomly to one of 6 different treatment
groups making up a 3 x 2 factorial design (Table 2). The day before the
microdialysis session, each animal was fitted with a plastic collar. The next day,
rats were weighed and habituated to the plexiglass chamber for at least 30 min.
The microdialysis probe, which was connected to a microsyringe pump (KD
Scientific, Model KDS250) via PE10 tubing that was slowing perfusing artificial
cerebral spinal fluid (aCSF; consisting of: 145 mM sodium chloride, 2.7mM
potassium chloride, 1 mM magnesium chloride, 1.2 calcium chloride, and 2.0 mM
sodium phosphate) through the probe at a flow rate of 1.2 μl/min, was inserted into
the guide cannula and the animal was connected to the swivel system by attaching
a leash to the collar. The rats were then habituated to the Plexiglas chamber and
probe insertion for at least 3.5 hr prior to collection of the baseline samples.
Baseline samples were collected into polyethylene microfuge tubes containing 5 μl
of 0.1 N perchloric acid every 20 min for 60 min. After collection of 3 baseline
samples, each rat was administered either saline or lobeline (1 or 3 mg/kg, SC) and
5 min later injected with saline or methamphetamine (0.5 mg/kg, IP).
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Table 4.1 Experimental groups in Experiment 2.
Pretreatment (Inj 1)

Treatment (Inj 2)

n

SAL

SAL

4

SAL

METH 0.5 mg/kg

6

LOB 1 mg/kg

SAL

6

LOB 1 mg/kg

METH 0.5 mg/kg

7

LOB 3 mg/kg

SAL

6

LOB 3 mg/kg

METH 0.5 mg/kg

7

Dialysis samples were collected every 20 min for an additional 3 hr after the
second injection. Samples were frozen immediately on dry ice and stored at -70˚ C
for later analysis. Following the microdialysis experiment, the brains were removed
and flash frozen in Chromasolv® (Sigma). Brains were sectioned into 40 μm
coronal slices, mounted onto slides and stained with cresyl violet. Microdialysis
probe placement in the nucleus accumbens was confirmed as indicated by Paxinos
and Watson (1986) and only data from rats with confirmed probe placement were
included.

Analysis of Extracellular Dopamine and DOPAC using HPLC-EC
Samples were thawed and analyzed immediately for dopamine and DOPAC
(3,4-dihydroxy-phenylacetic acid ) using HPLC-EC (ESA Chelmsford, MA, USA) as
previously described (Rahman et al., 2003). The system consisted of a computer
running EZ-Chrome Elite software, a solvent delivery system (ESA pump 582), a 3
μm, C18 column with guard column, a Coulochem III 5200A electrochemical
detector and manual injector equipped with an ESA 5011 analytical cell and 5020
guard cell. The guard cell was set at 225 mV, the reference electrode on at –
150mV and the working electrode was 225mV. The gain was set to 1μ A and
changed to 10 nA at 4.5 min in order to assess both DOPAC and DA in the same
sample. The mobile phase consisted of: 75 mM NaH2PO4, 1.7 nM 1-octanesulfonic
acid, 25 μM EDTA, 100 μl/l triethylamine and 10 % acetonitrile; pH 3.0 adjusted with
phosphoric acid, and pumped through the system at a rate of 0.65 ml/min. Samples
were loaded into a 20 μl sample loop and manually injected onto an analytical
column (BetaBasic-18 column, 150 mm x 3mm; Keystone Scientific, PA, USA).
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External standards were used to determine the actual concentrations of dopamine
and DOPAC in each sample.

Data Analysis
Data were recorded as peak height for DOPAC and dopamine for each
sample collected. These data were then expressed as a percent of baseline
(average of the 1st three samples) and analyzed with SPSS (Chicago, IL) software
using 2-way repeated measures ANOVA (Treatment Group x Time). In addition,
area under the curve was calculated for each experimental group and analyzed with
a one way ANOVA across treatment group. Post-hoc analyses for between-subject
effects were conducted using unpaired t- tests and paired t-tests with correction for
family wise error were used to compare within-subject data points.

Results
Histology

A/P: 1.6

A/P: 1.7

A/P: 2.2

Figure 4.1 Placement of Microdialysis Probes. Each vertical bar represents an
animal that was included in the analysis of the microdialysis experiment.

Analysis of Extracellular Dopamine in the Nucleus Accumbens Shell
The mean (± SEM) basal dopamine concentration was 0.60 ± 0.05 nM and
the basal DOPAC concentration was 471 ± 24 nM. An overall analysis of dopamine
levels using a 5 (treatment group) x 12 (time) mixed factor ANOVA with treatment
group as a between subject variable and time as a within subject variable indicated
significant main effects of group (F(4,27)=4.54; p<0.01) and time (F(11,297)=24.74;
p<0.01). This analysis also indicated a significant group x time interaction
(F(44,297)=4.27; p<0.01). Posthoc analysis indicated that the groups receiving
methamphetamine (0.5 mg/kg) showed a significant increase in dopamine levels
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compared to baseline (Figure 4.2; p<0.05). Analysis of the area under the curve for
each group indicated a significant groups effect (F(4,27)=5.25;p<0.01). Posthoc
analysis indicated none of the methamphetamine treatment groups were
significantly different from each other. Interestingly, lobeline had no effect on the
methamphetamine-induced increase in dopamine, nor did it have any effect when
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Figure 4.2 Extracellular Dopamine Levels in the Nucleus Accumbens
Shell. Mean (± SEM) percent baseline of the dopamine peak height for each time
point following administration of lobeline (LOB) and/or methamphetamine (METH).
The arrow indicates time of treatment. Symbols indicate differences from the
respective group’s baseline. The thick dashed line represents the baseline. The
insert is the calculated area under the curve for each group.

Analysis of Extracellular DOPAC in the Nucleus Accumbens Shell
An overall analysis of DOPAC levels using a 5 (treatment group) x 12 (time) mixed
factor ANOVA, with treatment group as a between subject variable and time as a
within subject variable, indicated significant main effects of group (F(4,27)=11.21;
p<0.01) and time (F(11,297)=8.91; p<0.01). This analysis also indicated a
significant group x time interaction (F(44,297)=7.96; p<0.01). Posthoc analysis
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indicated that the groups receiving methamphetamine (0.5 mg/kg) showed a
significant decrease in DOPAC levels compared to baseline (Figure 4.3; p<0.05).
Furthermore, lobeline administration significantly enhanced this decrease in a dosedependent manner (p<0.05). Analysis of the area under the curve for each group
indicated a significant groups effect (F(4,27)=9.14; p<0.01). Posthoc analysis
indicated none of the methamphetamine treatment groups were significantly
different from each other. Interestingly, while lobeline enhanced the
methamphetamine-induced decrease in DOPAC, it increased DOPAC levels dosedependently when administered alone (p<0.05).
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Summary of Experiment 3
Microdialysis was conducted in awake, freely moving rats with probe
placements in the nucleus accumbens shell. Methamphetamine administration
increased extracellular levels of dopamine in this brain region to ~ 450% of
baseline, while lobeline alone had no effect. Contrary to our hypothesis,
pretreatment with either dose of lobeline (1 or 3 mg/kg) did not significantly alter the
methamphetamine-induced increase in dopamine. However, a slight attenuation
following the higher dose of lobeline (3 mg/kg) at 60 min was noted. Interestingly,
lobeline alone increased DOPAC (~20%) at both doses tested, indicating an
increase in dopamine metabolism. As expected, methamphetamine alone
decreased DOPAC by ~30%, indicating a decrease in dopamine metabolism.
Lobeline pretreatment dose dependently enhanced the methamphetamine-induced
decrease, indicating synergistic inhibition of dopamine metabolism when lobeline
was administered prior to methamphetamine. Specifically, lobeline (1 and 3 mg/kg)
pretreatment prior to methamphetamine induced a more pronounced decrease in
DOPAC at 60 min than methamphetamine alone. Furthermore, the higher dose of
lobeline (3 mg/kg) combined with methamphetamine decreased extracellular
DOPAC for a longer period of time than methamphetamine alone.
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CHAPTER FIVE
General Discussion

The overall hypothesis of the current experiments was that lobeline would
block the acquisition and expression of methamphetamine-induced CPP and that
this behavioral effect would be associated with an inhibition of methamphetamineinduced dopamine release in the reward-relevant nucleus accumbens shell.
Previous behavioral research has indicated that lobeline is effective at attenuating
self-administration in rats, a behavior that is acquired and maintained through
operant conditioning. In the current studies, the effects of lobeline on
methamphetamine-induced behaviors that are learned through classical
conditioning were assessed. Through this type of learning, environmental cues that
were previously predictive of drug reward come to elicit a conditioned response,
which is thought to contribute significantly to context-dependent relapse in humans.
Few studies have examined the effects of low doses of lobeline (≤ 1 mg/kg)
following repeated administration. This dose of lobeline does not result in the nonspecific suppression of activity as is observed following the higher doses. For
example, lobeline (1 mg/kg) does not acutely decrease response rates in the drug
discrimination paradigm in animals trained to discriminate nicotine or
methamphetamine nor does this dose decrease operant responding for
methamphetamine or food reinforcement (Damaj, Patrick, Creasy, & Martin, 1997;
Harrod et al., 2001; Miller et al., 2003). However, this dose of lobeline is
behaviorally activity as it produces a conditioned taste aversion to a salt solution
and has been shown to decrease the progressive ratio breakpoint for intracranial
self-stimulation in rats (Harrod, Dwoskin, & Bardo, 2004; Wellman et al., 2008).
This latter study also suggests that lobeline is not reinforcing as drugs of abuse
increase the progressive ratio breakpoint for intracranial self-stimulation in rats. The
current experiments are the first to demonstrate that lobeline (1.0 mg/kg) also
attenuates methamphetamine-induced reward and future studies assessing the
repeated effects of lower doses of lobeline are warranted.
Following acute administration of lobeline (≥ 3 mg/kg), a non-specific
decrease in activity is often observed. Tolerance to these non-specific effects is
generally evident within ~5-7 repeated administrations. In addition to locomotor
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hypoactivity, as was observed in the current studies, higher doses of lobeline
acutely decrease response rates in drug discrimination and operant responding for
food (Harrod et al., 2001; Miller et al., 2001). Little is known about the
mechanism(s) underlying the lobeline-induced decrease in activity. Currently, there
are no known pharmacological manipulations that will block this hypoactivity
following lobeline (≥ 3 mg/kg), making it difficult to know with certainty that acute
administration of these doses decreases methamphetamine reward specifically and
is not simply disrupting ongoing behavior in a non-specific manner.
Lobeline, which is a nicotinic receptor ligand, is known to reliably produce
emesis or nausea in humans and this illness-inducing effect may explain the
decrease in behavior observed in rats (Dwoskin & Crooks, 2002). Interestingly,
while nicotine also produces a non-specific decrease in behavior when administered
acutely, the non-specific, non-selective, nicotinic receptor antagonist mecamylamine
blocks nicotine-induced hypoactivity, while having no effect on lobeline-induced
hypoactivity (Damaj et al., 1997). This suggests that while acute nicotine and
lobeline administration produce a similar non-specific decrease in behavior, they do
so via different pharmacological mechanisms.
Research has suggested that neuronal nicotinic receptors modulate
amphetamine-induced behaviors. Antagonism of nicotinic receptors with
mecamylamine prior to repeated amphetamine administration attenuates
amphetamine-induced locomotor sensitization; interestingly, after amphetamine
sensitization is established, mecamylamine has no effect on amphetamine-induced
hyperactivity (Schoffelmeer, De Vries, Wardeh, Van De Ven, & Vanderschuren,
2002). This study suggests neuronal nicotinic receptors modulate amphetamineinduced neuronal alterations. Since lobeline is known to act as a nicotinic receptor
antagonist, it is possible that this mechanism contributes to the lobeline-induced
disruption of methamphetamine reward. It is unlikely that antagonism of nicotinic
receptors alone is responsible for the disruption of methamphetamine-induced CPP
in the current study, as mecamylamine administration does not affect acquisition of
methamphetamine self-administration, nor does it disrupt fully acquired
methamphetamine self-administration (unpublished results from our laboratory).
Evidence suggests that nicotinic receptor activity may be an important mechanism
for the persistence of the effect of lobeline on methamphetamine reward. This
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evidence is based on work showing that lobelane, an analog of lobeline, selectively
and potently inhibits the vesicular monoamine transporter and the dopamine
transporter more potently than lobeline (Miller et al., 2004). However, lobelane
interacts with the nicotinic receptors less potently than lobeline (Miller et al., 2004).
Similar to lobeline, lobelane was shown to acutely decrease methamphetamine selfadministration (Neugebauer et al., 2007). However, rapid tolerance developed to
the lobelane-induced decrease in methamphetamine self-administration upon
repeated administration, suggesting that nicotinic receptor binding may be
necessary for the persistent decrease in methamphetamine self-administration
observed following repeated lobeline. Further understanding of the role that
nicotinic receptors play in psychostimulant-induced behaviors is necessary to fully
characterize the contribution this mechanism may have on the persistent nature of
lobeline-induced decreases of methamphetamine-induced behaviors.
Lobeline may be acting to decrease acquisition of methamphetamineinduced CPP by inducing disruptions in the mechanisms involved in Pavlovian
learning. It is currently unknown if lobeline affects these mechanisms. One would
expect that if lobeline (3 mg/kg) were impairing the formation of environmental and
drug reward associations then this dose of lobeline would block the acquisition at all
methamphetamine conditioning doses, not just the 0.5 mg/kg dose as demonstrated
in experiment 1. Since this was not the case, it is unlikely that the results obtained
here reflect merely a disruption in Pavlovian learning.
Taken together, the results from the present behavioral experiments
demonstrate that lobeline has differential effects on the acquisition and expression
of methamphetamine-induced CPP, as well as methamphetamine-induced
locomotor hyperactivity. Lobeline (1 and 3 mg/kg) blocked the acquisition of CPP
when given in combination with a low dose of methamphetamine (0.5 mg/kg) during
the conditioning phase. While only the higher dose of lobeline (3 mg/kg) acutely
blocked the expression of CPP, a blockade was observed following repeated
administration of both doses (1 and 3 mg/kg). As discussed in the introduction,
amphetamine CPP is not dependent on locomotor activity (i.e. restrained rats will
acquire CPP). However, the effect of locomotor hypoactivity during
postconditioning tests is not entirely clear. It is unlikely that the hypoactivity
contributes significantly to the disruption of CPP as a correlational analysis
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indicated that no relationship exists between locomotor activity and conditioned
place preference during the postconditioning tests
While both psychostimulant-induced reward and locomotor hyperactivity are
dependent on mesolimbic dopamine pathways, they appear to be due to
independent processes (Carr et al., 1988). Dissociation between conditioned
reward and locomotor hyperactivity has been observed previously with
amphetamine and these behaviors may be regulated by anatomically distinct
regions of the nucleus accumbens (Sellings & Clarke, 2003). Sellings and Clarke
(2003) assessed rats with bilateral 6-hydroxydopamine lesions of the nucleus
accumbens core or shell on CPP acquisition, CPP expression and locomotor
activity induced with amphetamine (0.75 mg/kg). Their results indicate that the
nucleus accumbens shell meditates amphetamine-induced reward, as lesions in this
area inhibited acquisition and expression of amphetamine-induced CPP, while
having no effect on amphetamine-induced locomotor hyperactivity. In addition,
lesions of the nucleus accumbens core did not disrupt acquisition or expression of
amphetamine-induced CPP, but did attenuate amphetamine-induced locomotor
hyperactivity.
The nucleus accumbens shell has been implicated in reward-related
behaviors. Previous research has shown that rats will self-administer amphetamine
directly into this brain region (Hoebel et al., 1983). In addition, intracranial
administration of amphetamine into this brain region results in CPP (McBride et al.,
1999; Schildein, Agmo, Huston, & Schwarting, 1998). Furthermore, the rewarding
effects of amphetamine can be blocked by 6-hydroxydopamine lesions of the
nucleus accumbens shell, as well as local administration of D1 or D2 antagonists
(Hoffman & Beninger, 1989; Spyraki et al., 1982). These studies indicate that intact
dopaminergic mechanisms in the nucleus accumbens shell are critically important
for amphetamine-induced reward. Based on these results, we hypothesized that
the effects observed in the current study are a result of lobeline blocking the
amphetamine-induced increase of extracellular dopamine levels in the nucleus
accumbens shell.
To test this hypothesis, we examined the effect of lobeline on
methamphetamine-evoked dopamine release in the nucleus accumbens shell using
in vivo microdialysis. Dopamine levels in the nucleus accumbens shell were
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increased (~450%) following administration of a relatively low dose of
methamphetamine (0.5 mg/kg, SC). In addition, a concomitant decrease in
extracellular DOPAC (~30%) was evident. This dose of methamphetamine (0.5
mg/kg) does not cause neurotoxicity and is a weak inhibiter of monoamine oxidase
(Miller, Shore, & Clarke, 1980). It has been suggested previously that the
methamphetamine-induced decrease in DOPAC may be due to the redistribution of
newly synthesized dopamine such that it is not available for monoamine oxidase
degradation (Shimosato, Nagao, Watanabe, & Kitayama, 2003). In addition,
methamphetamine-induced reversal of the dopamine transporter presumably results
in less dopamine available for metabolism to DOPAC in the cytosol.
The current results demonstrate that lobeline (1 or 3 mg/kg) alone has no
effect on extracellular dopamine levels in the nucleus accumbens shell, but does
increase the extracellular concentration of DOPAC (~20%). These results coincide
with previous findings indicating that administration of a high dose of lobeline (10
mg/kg) does not alter extracellular dopamine levels in striatum as assessed with in
vivo microdialysis in awake rats (Eyerman & Yamamoto, 2005). Unfortunately, dose
comparisons cannot be made with regard to DOPAC, as this was not reported in the
study by Eyerman & Yamamoto (2005). However, another report using in vivo
microdialysis to assess the effects of lobeline in nicotine pretreated rats in the
nucleus accumbens core indicated lobeline alone (10 mg/kg, IP) did not affect
extracellular dopamine or DOPAC (Benwell & Balfour, 1998). The reason for the
discrepancy in results between the study by Benwell and Balfour (1998) and the
current study may be due to neuroanatomical differences between the shell and
core subregions on the nucleus accumbens (see above). Finally, when lobeline (2,
4, 6 nmol at a rate of 2 μl/min for 1 min) is perfused directly into the rat striatum via
a microdialysis probe, a dose-dependent increase in extracellular dopamine is
observed; however, DOPAC levels were not reported in this study (Lecca, Shim,
Costa, & Javaid, 2000). Since little is known about the diffusion properties of
lobeline, it is unclear whether the tissue concentrations achieved around the
microdialysis probe in this latter study are comparable to those achieved via
systemic administration. Differences in tissue concentrations of lobeline in the
target region could account for the differences observed.
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Previous research using an in vitro superfused striatal slice preparation has
demonstrated that a low concentration of lobeline (1 µM) has little effect on
dopamine release, while increasing DOPAC (Teng et al., 1997). However, higher
concentrations (100 µM) of lobeline result in dopamine release (Teng et al., 1997).
The dopamine release observed at the higher concentration is thought to occur
when dopamine levels in the cytosol exceed the enzymatic capabilities of
monoamine oxidase (Teng et al., 1997). Interestingly, pharmacokinetic data
indicates that when a rat is administered lobeline (4.0 mg/kg; SC) the resulting brain
concentration is 237 ng/ml (or ~0. 7 μM), indicating that the findings with the lower
concentrations are more likely relevant for comparison to in vivo experiments which
typically use lobeline doses between 0.3 – 10 mg/kg (Reavill, Walther, Stolerman,
& Testa, 1990). Importantly, the brain concentration of lobeline achieved following
systemic administration of 4.0 mg/kg is similar to the IC50 for lobeline inhibition of
[3H]DA uptake into vesicles (0.88 μM) in vitro, which is thought to be the primary
mechanism responsible for the lobeline-induced decrease of methamphetamineinduced behaviors (Dwoskin & Crooks, 2002; Teng et al., 1997). The differences
between in vivo and in vitro findings are probably due to differences in lobeline
concentration, as the systemic lobeline doses administered in the current study do
not result in a brain concentration high enough to increase extracellular dopamine
levels.
It is well accepted that increases or decreases in extracellular DOPAC are, at
least in part, the result of altered vesicular storage of dopamine (Eisenhofer, Kopin,
& Goldstein, 2004). As described in the introduction, amphetamine and lobeline
have been shown to interact with the vesicular monoamine transporter. It is likely
that the lobeline induced increase in DOPAC observed in the current study is due to
inhibition of dopamine uptake into vesicles, allowing for more cytosolic dopamine to
be available for monoamine oxidase metabolism to DOPAC (Teng et al., 1998). In
contrast, the decreases in DOPAC following methamphetamine in the current study
are likely due to the redistribution of newly synthesized dopamine in such a manner
that it is not physically available to monoamine oxide for metabolism (Zetterstrom,
Sharp, Collin, & Ungerstedt, 1988). It is possible, albeit less likely, that the dose of
methamphetamine used in the current study inhibits the activity monoamine
oxidase. The ability of amphetamine to decrease monoamine oxidase activity is
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observed following higher systemic doses than those administered in the current
study (Miller et al., 1980).
No previous in vivo studies have reported that lobeline administration alone
results in increased extracellular DOPAC, while simultaneously enhancing the
methamphetamine-induced decrease. One possibility for this outcome is that
lobeline may alter the methamphetamine-induced metabolism of DA to DOPAC in
the cytoplasm; however, previous in vitro research indicates that lobeline does not
inhibit monoamine oxidase (Miller et al., 2001). While the current studies do not
address this question directly, it is unlikely that lobeline alters the enzymatic activity
involved in metabolizing dopamine to DOPAC. During this process, monoamine
oxidase deaminates dopamine to 3,4-dihydroxyphenylacetaldehype, which is then
oxidized by aldehyde dehydrogenase to DOPAC (Eisenhofer et al., 2004). If
lobeline were decreasing the enzymatic activity of either of these enzymes, a
decrease in DOPAC would be expected. Likewise, an increase in the activity of
these enzymes would be expected to result in an increase in DOPAC. It seems
unlikely that lobeline would increase the activity of these enzymes when
administered alone, but conversely decrease the activity of these enzymes in
combination with methamphetamine. Thus, the current results suggest the effect of
lobeline, as well as the effect of lobeline pretreatment prior to methamphetamine
administration, is not due to interactions with enzymatic pathway responsible for
converting dopamine to DOPAC.
As an alternative explanation, recent studies have suggested that
psychostimulants can interact with proteins that help regulate and maintain the
reserve and readily releasable dopamine stores (Venton et al., 2006). One
possibility for the current microdialysis study results is that methamphetamine
induces a redistribution of a portion of the readily-releasable vesicular stores of
dopamine to a site within the cytosol that renders dopamine not sequestered in
vesicles to be less likely to interact with monoamine oxidase. This would result in
increased dopamine available for reverse transport. While there is currently no
information available about interactions of lobeline with other vesicular proteins,
perhaps methamphetamine changes the dynamics of lobeline’s interactions with the
vesicular membrane such that lobeline and amphetamine act synergistically to
redistribute cytosolic dopamine stores. This could result in further decreases in
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DOPAC due to a decrease of cytosolic dopamine in a region where monoamine
oxidase has access to it. Thus, lobeline may act to redistribute cytosolic dopamine
pools such that when methamphetamine is available, dopamine is unavailable for
metabolism. The mechanisms responsible for these putative effects remain to be
elucidated.
No significant effect of lobeline on the methamphetamine-evoked increase in
extracellular dopamine was observed in the current experiment, although a slight
decrease was noted at the 60-min time point. These results are consistent with
findings reported by Eyerman and Yamamoto (2005) indicating that lobeline (10
mg/kg) does not acutely attenuate extracellular dopamine levels in the striatum
following methamphetamine (10 mg/kg). In contrast, in vitro studies indicate that
lobeline (0.3 and 1.0 μM) decreases amphetamine (1.0 μM) -evoked endogenous
dopamine release in rat striatal tissue, indicating a discrepancy between in vivo and
in vitro effects of lobeline (Miller et al., 2001). Additionally, a recent study using a
human embryonic kidney cell system expressing isoforms of both the dopamine
transporter and vesicular monoamine transporter found that lobeline (100 μM)
decreases methamphetamine-evoked [3H]DA release (Wilhelm, Johnson,
Eshleman, & Janowsky, 2008). Differences among these studies in the effect of
lobeline on methamphetamine-induced increases in dopamine levels likely reflect
inherent differences between in vivo preparations using intact animals and in vitro
preparations examining only a part of the neurocircuitry involved in the drug effects.
Since lobeline administration decreases methamphetamine-induced
behaviors, it is possible that lobeline may enhance the peripheral metabolism of
methamphetamine. While it is currently unknown if lobeline alters
methamphetamine brain concentrations, the current results showing that lobeline
does not alter methamphetamine-induced dopamine release in the nucleus
accumbens shell argues against a potential pharmacokinetic interpretation. Based
on such a pharmacokinetic interpretation, lobeline should have attenuated the
methamphetamine-induced increase in extracellular dopamine levels.
Lobeline (3 mg/kg) pretreatment has been shown to decrease
methamphetamine self-administration and conditioned place preference, which
suggests that lobeline may be attenuating the effects of methamphetamine
reinforced behavior via mechanisms other than extracellular dopamine levels in the
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nucleus accumbens shell. Another possibility is that lobeline may decrease
methamphetamine-evoked dopamine release more completely following repeated
administration. To date, it can not be concluded with certainty that acute lobeline (3
mg/kg) is specifically decreasing methamphetamine reward, rather than having nonspecific effects. Following repeated administration, lobeline (3 mg/kg) more
specifically decreases methamphetamine self-administration and the expression of
CPP, while having a decreased effect on other behaviors (i.e. responding for
sucrose reinforcement or locomotor activity) Harrod et al., 2001). Thus,
methamphetamine-evoked increases in extracellular dopamine levels may be
decreased following repeated lobeline administration. In any case, the current
studies emphasis the importance of assessing potential pharmacotherapies
following repeated administration and including doses that do not affect behavior
acutely.

Integration with Previous Work
Lobeline has been purposed to be a potential pharmacotherapy for
psychostimulant addiction, attributable in part to its unique pharmacological profile
(Dwoskin & Crooks, 2002). Elucidating the mechanisms by which lobeline reduces
the rewarding effects of psychostimulants would aid in the development of
pharmacotherapies for the treatment of drug dependence. It is unlikely that all of
lobeline’s pharmacological mechanisms are currently known and future research
will surely uncover additional molecular targets with which lobeline interacts.
Lobeline has been shown to reduce methamphetamine self-administration in rats,
indicating it decreases the primary reinforcing effects of methamphetamine (Harrod
et al., 2001). The current studies indicate that lobeline is also effective at
attenuating the conditioned environmental cues associated with methamphetamine
administration. In addition, the effects of lobeline on cocaine-induced behaviors
have also been examined. Interestingly, lobeline decreases cocaine selfadministration and acquisition of conditioned place preference. One could
speculate that nicotinic receptor antagonism, such as that provided by lobeline, may
be a common pharmacological target for both methamphetamine and cocaine.
However, additional studies have indicated that mecamylamine does not alter the
acquisition of methamphetamine self-administration nor does alter stable
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methamphetamine self-administration. Taken together, these experiments suggest
that lobeline is likely decreasing psychostimulant-induced behaviors by altering the
transport vesicular dopamine stores within the presynaptic terminal. Since both
methamphetamine self-administration and conditioned place preference were
attenuated by lobeline, these results suggest that both the primary rewarding and
the secondary cue-elicited rewarding effects of methamphetamine involve VMAT2.

Limitations
Locomotor activity is a commonly reported behavioral measure of
psychostimulant-induced behavior. While the automation of many various types of
behavioral testing apparatuses has provided efficient data collection, it is unclear
how sensitive each of these automated indices are to different drug treatments. For
example, in Experiment 1, lobeline did not cause hypoactivity compared to controls
following the 4th administration of lobeline when animals were confined to one
compartment (last conditioning day). However, hypoactivity was still observed
following the 5th administration of lobeline when animals were allowed access to the
entire chamber (postconditioning tests). Since lobeline has been shown to be
behaviorally active for ~30 min, these differences in observed locomotor activity
may be due to the differences in test session length, as the conditioning sessions
were 30 min and the postconditioning tests were 15 min (Harrod et al., 2001).
While it is informative to have locomotor activity data during CPP experiments,
close examination of the testing apparatus and time course effects are necessary
for comparisons across studies.
The dose of methamphetamine used for the microdialysis study is on the low
end of its dose effect curve for most behaviors and results from our laboratory
suggest that 0.5 mg/kg of methamphetamine is a threshold dose for acquisition of
CPP. While it appears that lobeline may have attenuated methamphetamineevoked dopamine release, this effect failed to reach significance. Upon closer
examination of these groups, it is evident that there was greater variability in the
peak effects of the methamphetamine-induced increase in dopamine than in the
lobeline alone groups. The effects of lobeline may have been masked due to the
variability in response to methamphetamine at this dose. One likely contributing
factor for the variability relates to the probe placement. Although all probes were in
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the nucleus accumbens shell, portions of the probe extended beyond the shell.
Smaller probes and stricter criteria for data inclusion based on probe placement
may be useful for reducing this variability.
The current study did not address the possibility that acquisition of lobeline
CPP may be state dependent. State dependent learning is the phenomenon in
which expression of a learned behavior occurs only when an organism is in the
same physiological or contextual state during recall as it was during learning
(Overton, 1991). It cannot be ruled out that lobeline alone is not rewarding in this
paradigm, as the learned association between reward and environmental cues may
be state-dependent. In order to assess this, rats given lobeline during the
conditioning phase would need to be given lobeline prior to the postconditioning
test. It is possible that lobeline CPP would be evident only when rats are in the
same drug state as they were during conditioning. Interestingly, like in the current
study, previous assessment of lobeline-induced CPP did not address the issue,
indicating that more work is needed (Fudala & Iwamoto, 1986).

Future Directions
Recent evidence suggests that, in addition to its effect on dopaminergic
mechanisms, lobeline may function as a mu opioid receptor antagonist (Miller et al.,
2007). The mu-opioid system is thought to play a role in cue-induced drug-seeking
behavior, as assessed using cue and drug-primed reinstatement of
methamphetamine seeking behavior in rats, as well as using sensitization to
methamphetamine (Anggadiredja, Sakimura, Hiranita, & Yamamoto, 2004). In
addition, mu-opioid receptor antagonists have been shown to decrease
amphetamine-induced increases in dopamine levels in the nucleus accumbens
(Chiu, Ma, & Ho, 2006; Schad, Justice, & Holtzman, 1996). It is currently unknown
if mu opioid antagonists decrease rodent amphetamine self-administration when
given repeatedly; however, there is some indication that the opiate antagonist
naltrexone may be useful as an adjunct pharmacotherapy for amphetamine
dependence in humans (Jayaram-Lindstrom, Wennberg, Beck, & Franck, 2005).
Further characterization of lobeline’s ability to attenuate the psychoactive effects of
opiates and how this pharmacological action may interact with methamphetamine
conditioned reward is warranted.
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As suggested previously, the effects of repeated administration of lobeline on
methamphetamine-induced behaviors warrants further investigation. While
previous studies have shown that lobeline does not attenuate reinstatement of
methamphetamine-seeking specifically, only acute effects of this dose were
assessed (Harrod et al., 2003). Since repeated administration of lobeline blocked
the expression of CPP, it is of interest to assess the effects of repeated lobeline on
drug and cue-induced reinstatement in the operant paradigm. The current results
suggest that repeated administration of lobeline may be more efficacious in
attenuating reinstatement.
In summary, lobeline has many pharmacological actions that may contribute
to its potential usefulness as a pharmacotherapy for psychostimulant dependence.
It may be that a combination of pharmacological actions is necessary for the
decrease observed in methamphetamine behaviors following lobeline
administration. In addition, while self-administration is a standard procedure used
to assess the direct reinforcing properties of drugs of abuse, differential results may
be observed when assessing potential pharmacotherapies using the CPP paradigm.
Perhaps pharmacotherapies that interact with a combination of molecular targets
may be more effective than highly specific pharmacotherapies in attenuating the
primary and secondary reinforcing properties of methamphetamine.

Copyright © Nichole Marie Neugebauer 2008

56

REFERENCES
Anagnostaras, S. G., & Robinson, T. E. (1996). Sensitization to the psychomotor
stimulant effects of amphetamine: modulation by associative learning. Behav
Neurosci, 110(6), 1397-1414.
Anggadiredja, K., Sakimura, K., Hiranita, T., & Yamamoto, T. (2004). Naltrexone
attenuates cue- but not drug-induced methamphetamine seeking: a possible
mechanism for the dissociation of primary and secondary reward. Brain Res,
1021(2), 272-276.
Ary, T. E., & Komiskey, H. L. (1980). Phencyclidine: effect on the accumulation of
3H-dopamine in synaptic vesicles. Life Sci, 26(7), 575-578.
Bardo, M. T. (1998). Neuropharmacological mechanisms of drug reward: beyond
dopamine in the nucleus accumbens. . Crit Rev Neurobiol, 12(1-2), 37-67.
Bardo, M. T., & Bevins, R. A. (2000). Conditioned place preference: what does it
add to our preclinical understanding of drug reward? Psychopharmacology
(Berl), 153(1), 31-43.
Benwell, M. E., & Balfour, D. J. (1998). The influence of lobeline on nucleus
accumbens dopamine and locomotor responses to nicotine in nicotinepretreated rats. Br J Pharmacol, 125(6), 1115-1119.
Berke, J. D., & Hyman, S. E. (2000). Addiction, dopamine, and the molecular
mechanisms of memory. Neuron, 25(3), 515-532.
Bhat, R. V., Turner, S. L., Selvaag, S. R., Marks, M. J., & Collins, A. C. (1991).
Regulation of brain nicotinic receptors by chronic agonist infusion. J
Neurochem, 56(6), 1932-1939.
Boileau, I., Dagher, A., Leyton, M., Welfeld, K., Booij, L., Diksic, M., et al. (2007).
Conditioned dopamine release in humans: a positron emission tomography
[11C]raclopride study with amphetamine. J Neurosci, 27(15), 3998-4003.
Brioni, J. D., Decker, M. W., Sullivan, J. P., & Arneric, S. P. (1997). The
pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv
Pharmacol, 37, 153-214.
Brown, J. M., Hanson, G. R., & Fleckenstein, A. E. (2000). Methamphetamine
rapidly decreases vesicular dopamine uptake. J Neurochem, 74(5), 22212223.

57

Carr, G. D., Phillips, A. G., & Fibiger, H. C. (1988). Independence of amphetamine
reward from locomotor stimulation demonstrated by conditioned place
preference. Psychopharmacology (Berl), 94(2), 221-226.
Carr, G. D., & White, N. M. (1983). Conditioned place preference from intraaccumbens but not intra-caudate amphetamine injections. Life Sci, 33(25),
2551-2557.
Childress, A. R., Mozley, P. D., McElgin, W., Fitzgerald, J., Reivich, M., & O'Brien,
C. P. (1999). Limbic activation during cue-induced cocaine craving. Am J
Psychiatry, 156(1), 11-18.
Chiu, C. T., Ma, T., & Ho, I. K. (2006). Methamphetamine-induced behavioral
sensitization in mice: alterations in mu-opioid receptor. J Biomed Sci, 13(6),
797-811.
Cho, A. K., Melega, W. P., Kuczenski, R., & Segal, D. S. (2001). Relevance of
pharmacokinetic parameters in animal models of methamphetamine abuse.
Synapse, 39(2), 161-166.
Cook, C. E., Jeffcoat, A. R., Hill, J. M., Pugh, D. E., Patetta, P. K., Sadler, B. M., et
al. (1993). Pharmacokinetics of methamphetamine self-administered to
human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug
Metab Dispos, 21(4), 717-723.
Cooper, J. R., Bloom, F. E., & Roth, R. H. (2003). The biochemical basis of
neuropharmacology (8th ed). Oxford ; New York: Oxford University Press.
Damaj, M. I., Patrick, G. S., Creasy, K. R., & Martin, B. R. (1997). Pharmacology of
lobeline, a nicotinic receptor ligand. J Pharmacol Exp Ther, 282(1), 410-419.
Dani, J. A., & De Biasi, M. (2001). Cellular mechanisms of nicotine addiction.
Pharmacol Biochem Behav, 70(4), 439-446.
DEA, U. S. D. E. A. Maps of methamphetamine laboratory incidents: calendar years
1999-2006. Retrieved. from
http://www.usdoj.gov/dea/concern/map_lab_seizures.html.
Decker, M. W., Majchrzak, M. J., & Arneric, S. P. (1993). Effects of lobeline, a
nicotinic receptor agonist, on learning and memory. Pharmacol Biochem
Behav, 45(3), 571-576.
Di Chiara, G. (1999). Drug addiction as dopamine-dependent associative learning
disorder. Eur J Pharmacol, 375(1-3), 13-30.

58

Drevets, W. C., Gautier, C., Price, J. C., Kupfer, D. J., Kinahan, P. E., Grace, A. A.,
et al. (2001). Amphetamine-induced dopamine release in human ventral
striatum correlates with euphoria. Biol Psychiatry, 49(2), 81-96.
Dwoskin, L. P., & Crooks, P. A. (2002). A novel mechanism of action and potential
use for lobeline as a treatment for psychostimulant abuse. Biochem
Pharmacol, 63(2), 89-98.
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004). Catecholamine metabolism: a
contemporary view with implications for physiology and medicine. Pharmacol
Rev, 56(3), 331-349.
Eyerman, D. J., & Yamamoto, B. K. (2005). Lobeline attenuates methamphetamineinduced changes in vesicular monoamine transporter 2 immunoreactivity and
monoamine depletions in the striatum. J Pharmacol Exp Ther, 312(1), 160169.
Fudala, P. J., & Iwamoto, E. T. (1986). Further studies on nicotine-induced
conditioned place preference in the rat. Pharmacol Biochem Behav, 25(5),
1041-1049.
Gardner, E. L. (2000). What we have learned about addiction from animal models of
drug self-administration. Am J Addict, 9(4), 285-313.
Gentry, W. B., Ghafoor, A. U., Wessinger, W. D., Laurenzana, E. M., Hendrickson,
H. P., & Owens, S. M. (2004). (+)-Methamphetamine-induced spontaneous
behavior in rats depends on route of (+)METH administration. Pharmacol
Biochem Behav, 79(4), 751-760.
Grace, A. A. (2002). Dopamine. In K. Davis (Ed.), Neuropsychopharmacology: the
fifth generation of progress: an official publication of the American College of
Neuropsycopharmacology. Philadelphia, PA: Lippincott Williams & Wilkins.
Grace, A. A., & Bunney, B. S. (1985). Opposing effects of striatonigral feedback
pathways on midbrain dopamine cell activity. Brain Res, 333(2), 271-284.
Harris, D. S., Boxenbaum, H., Everhart, E. T., Sequeira, G., Mendelson, J. E., &
Jones, R. T. (2003). The bioavailability of intranasal and smoked
methamphetamine. Clin Pharmacol Ther, 74(5), 475-486.
Harrod, S. B., Dwoskin, L. P., & Bardo, M. T. (2004). Lobeline produces conditioned
taste avoidance in rats. Pharmacol Biochem Behav, 78(1), 1-5.

59

Harrod, S. B., Dwoskin, L. P., Crooks, P. A., Klebaur, J. E., & Bardo, M. T. (2001).
Lobeline attenuates d-methamphetamine self-administration in rats. J
Pharmacol Exp Ther, 298(1), 172-179.
Harrod, S. B., Dwoskin, L. P., Green, T. A., Gehrke, B. J., & Bardo, M. T. (2003).
Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl),
165(4), 397-404.
Hiroi, N., & White, N. M. (1990). The reserpine-sensitive dopamine pool mediates
(+)-amphetamine-conditioned reward in the place preference paradigm.
Brain Res, 510(1), 33-42.
Hiroi, N., & White, N. M. (1991). The amphetamine conditioned place preference:
differential involvement of dopamine receptor subtypes and two
dopaminergic terminal areas. Brain Res, 552(1), 141-152.
Hoebel, B. G., Monaco, A. P., Hernandez, L., Aulisi, E. F., Stanley, B. G., & Lenard,
L. (1983). Self-injection of amphetamine directly into the brain.
Psychopharmacology (Berl), 81(2), 158-163.
Hoffman, D. C., & Beninger, R. J. (1989). The effects of selective dopamine D1 or
D2 receptor antagonists on the establishment of agonist-induced place
conditioning in rats. Pharmacol Biochem Behav, 33(2), 273-279.
Hyman, S. E., & Malenka, R. C. (2001). Addiction and the brain: the neurobiology of
compulsion and its persistence. Nat Rev Neurosci, 2(10), 695-703.
Ikemoto, S. (2007). Dopamine reward circuitry: Two projection systems from the
ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain
Res Rev.
Jayaram-Lindstrom, N., Wennberg, P., Beck, O., & Franck, J. (2005). An open
clinical trial of naltrexone for amphetamine dependence: compliance and
tolerability. Nord J Psychiatry, 59(3), 167-171.
Kalivas, P. W., & O'Brien, C. (2007). Drug Addiction as a Pathology of Staged
Neuroplasticity. Neuropsychopharmacology.
Kelley, A. E. (2004). Memory and addiction: shared neural circuitry and molecular
mechanisms. Neuron, 44(1), 161-179.
Kelley, A. E., & Berridge, K. C. (2002). The neuroscience of natural rewards:
relevance to addictive drugs. J Neurosci, 22(9), 3306-3311.

60

Kilts, C. D., Schweitzer, J. B., Quinn, C. K., Gross, R. E., Faber, T. L., Muhammad,
F., et al. (2001). Neural activity related to drug craving in cocaine addiction.
Arch Gen Psychiatry, 58(4), 334-341.
Koob, G. F. (1992). Drugs of abuse: anatomy, pharmacology and function of reward
pathways. Trends Pharmacol Sci, 13(5), 177-184.
Kuo, Y. M., Liang, K. C., Chen, H. H., Cherng, C. G., Lee, H. T., Lin, Y., et al.
(2007). Cocaine-but not methamphetamine-associated memory requires de
novo protein synthesis. Neurobiol Learn Mem, 87(1), 93-100.
Lecca, D., Shim, I., Costa, E., & Javaid, J. I. (2000). Striatal application of nicotine,
but not of lobeline, attenuates dopamine release in freely moving rats.
Neuropharmacology, 39(1), 88-98.
Liang, N. Y., & Rutledge, C. O. (1982). Comparison of the release of [3H]dopamine
from isolated corpus striatum by amphetamine, fenfluramine and unlabelled
dopamine. Biochem Pharmacol, 31(6), 983-992.
Liao, R. M., Chang, Y. H., & Wang, S. H. (1998). Influence of SCH23390 and
spiperone on the expression of conditioned place preference induced by damphetamine or cocaine in the rat. Chin J Physiol, 41(2), 85-92.
Ling, W., Rawson, R., Shoptaw, S., & Ling, W. (2006). Management of
methamphetamine abuse and dependence. Curr Psychiatry Rep, 8(5), 345354.
Lokwan, S. J., Overton, P. G., Berry, M. S., & Clark, D. (1999). Stimulation of the
pedunculopontine tegmental nucleus in the rat produces burst firing in A9
dopaminergic neurons. Neuroscience, 92(1), 245-254.
Lyness, W. H., Friedle, N. M., & Moore, K. E. (1979). Destruction of dopaminergic
nerve terminals in nucleus accumbens: effect on d-amphetamine selfadministration. Pharmacol Biochem Behav, 11(5), 553-556.
Mantle, T. J., Tipton, K. F., & Garrett, N. J. (1976). Inhibition of monoamine oxidase
by amphetamine and related compounds. Biochem Pharmacol, 25(18), 20732077.
McBride, W. J., Murphy, J. M., & Ikemoto, S. (1999). Localization of brain
reinforcement mechanisms: intracranial self-administration and intracranial
place-conditioning studies. Behav Brain Res, 101(2), 129-152.

61

Melega, W. P., Williams, A. E., Schmitz, D. A., DiStefano, E. W., & Cho, A. K.
(1995). Pharmacokinetic and pharmacodynamic analysis of the actions of Damphetamine and D-methamphetamine on the dopamine terminal. J
Pharmacol Exp Ther, 274(1), 90-96.
Milesi-Halle, A., Hendrickson, H. P., Laurenzana, E. M., Gentry, W. B., & Owens, S.
M. (2005). Sex- and dose-dependency in the pharmacokinetics and
pharmacodynamics of (+)-methamphetamine and its metabolite (+)amphetamine in rats. Toxicol Appl Pharmacol, 209(3), 203-213.
Miller, D. K., Crooks, P. A., & Dwoskin, L. P. (2000). Lobeline inhibits nicotineevoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked
(86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology, 39(13),
2654-2662.
Miller, D. K., Crooks, P. A., Teng, L., Witkin, J. M., Munzar, P., Goldberg, S. R., et
al. (2001). Lobeline inhibits the neurochemical and behavioral effects of
amphetamine. J Pharmacol Exp Ther, 296(3), 1023-1034.
Miller, D. K., Crooks, P. A., Zheng, G., Grinevich, V. P., Norrholm, S. D., & Dwoskin,
L. P. (2004). Lobeline analogs with enhanced affinity and selectivity for
plasmalemma and vesicular monoamine transporters. J Pharmacol Exp
Ther, 310(3), 1035-1045.
Miller, D. K., Harrod, S. B., Green, T. A., Wong, M. Y., Bardo, M. T., & Dwoskin, L.
P. (2003). Lobeline attenuates locomotor stimulation induced by repeated
nicotine administration in rats. Pharmacol Biochem Behav, 74(2), 279-286.
Miller, D. K., Lever, J. R., Rodvelt, K. R., Baskett, J. A., Will, M. J., & Kracke, G. R.
(2007). Lobeline, a potential pharmacotherapy for drug addiction, binds to mu
opioid receptors and diminishes the effects of opioid receptor agonists. Drug
Alcohol Depend, 89(2-3), 282-291.
Miller, H. H., Shore, P. A., & Clarke, D. E. (1980). In vivo monoamine oxidase
inhibition by d-amphetamine. Biochem Pharmacol, 29(10), 1347-1354.
NACO. (2007). The Meth Epidemic: The Changing Demographics of
Methamphetamine. Journal. Retrieved from www.naco.org/template.cfm
Neugebauer, N. M., Harrod, S. B., Stairs, D. J., Crooks, P. A., Dwoskin, L. P., &
Bardo, M. T. (2007). Lobelane decreases methamphetamine selfadministration in rats. Eur J Pharmacol, 571(1), 33-38.

62

NIDA. (2007a). Monitoring the Future: National Results on Adolescent Drug Use.
Overview of Key Findings, 2006. F Retrieved from
http://www.monitoringthefuture.org/pubs /monographs/overview2006.pdf
NIDA. (2007b). NIDA Study Suggests Crystal Methamphetamine Use in Young
Adults Higher than Previously Reported. Retrieved 9/02/2007, from
http://www.drugabuse.gov
O'Brien, C. P., Childress, A. R., & McLellan, A. T. (1991). Conditioning factors may
help to understand and prevent relapse in patients who are recovering from
drug dependence. NIDA Res Monogr, 106, 293-312.
Olmstead, M. C., & Franklin, K. B. (1994). Lesions of the pedunculopontine
tegmental nucleus block drug-induced reinforcement but not amphetamineinduced locomotion. Brain Res, 638(1-2), 29-35.
Overton, D. A. (1991). A historical perspective on drug discrimination. NIDA Res
Monogr(116), 5-24.
Parsons, L. H., & Justice, J. B., Jr. (1994). Quantitative approaches to in vivo brain
microdialysis. Crit Rev Neurobiol, 8(3), 189-220.
Pavlov, I. (1927). Conditioned reflexes; an investigation of the physiological activity
of the cerebral cortex. (T. G. Anrep, Trans.). London: Oxford University
press: Humphrey Milford.
Philippu, A., & Beyer, J. (1973). Dopamine and noradrenaline transport into
subcellular vesicles of the striatum. Naunyn Schmiedebergs Arch Pharmacol,
278(4), 387-402.
Pickens, R. W., & Crowder, W. F. (1967). Effects of CS-US interval on conditioning
of drug response, with assessment of speed of conditioning. .
Psychopharmacologia, 11(1), 89-94.
Prendergast, M., Podus, D., Finney, J., Greenwell, L., & Roll, J. (2006).
Contingency management for treatment of substance use disorders: a metaanalysis. Addiction, 101(11), 1546-1560.
Reavill, C., Walther, B., Stolerman, I. P., & Testa, B. (1990). Behavioural and
pharmacokinetic studies on nicotine, cytisine and lobeline.
Neuropharmacology, 29(7), 619-624.

63

Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., et
al. (2006). Contingency management for the treatment of methamphetamine
use disorders. Am J Psychiatry, 163(11), 1993-1999.
Schad, C. A., Justice, J. B., Jr., & Holtzman, S. G. (1996). Differential effects of
delta- and mu-opioid receptor antagonists on the amphetamine-induced
increase in extracellular dopamine in striatum and nucleus accumbens. J
Neurochem, 67(6), 2292-2299.
Schenk, S., & Partridge, B. (1997). Sensitization and tolerance in psychostimulant
self-administration. Pharmacol Biochem Behav, 57(3), 543-550.
Schildein, S., Agmo, A., Huston, J. P., & Schwarting, R. K. (1998). Intraaccumbens
injections of substance P, morphine and amphetamine: effects on
conditioned place preference and behavioral activity. Brain Res, 790(1-2),
185-194.
Schoffelmeer, A. N., De Vries, T. J., Wardeh, G., van de Ven, H. W., &
Vanderschuren, L. J. (2002). Psychostimulant-induced behavioral
sensitization depends on nicotinic receptor activation. J Neurosci, 22(8),
3269-3276.
Schuldiner, S. (1994). A molecular glimpse of vesicular monoamine transporters. J
Neurochem, 62(6), 2067-2078.
Seiden, L. S., Sabol, K. E., & Ricaurte, G. A. (1993). Amphetamine: effects on
catecholamine systems and behavior. Annu Rev Pharmacol Toxicol, 33, 639677.
Sellings, L. H., & Clarke, P. B. (2003). Segregation of amphetamine reward and
locomotor stimulation between nucleus accumbens medial shell and core. J
Neurosci, 23(15), 6295-6303.
Shimosato, K., Nagao, N., Watanabe, S., & Kitayama, S. (2003). Suppressive
effects of trihexyphenidyl on methamphetamine-induced dopamine release
as measured by in vivo microdialysis. Synapse, 49(1), 47-54.
Shoblock, J. R., Maisonneuve, I. M., & Glick, S. D. (2003). Differences between dmethamphetamine and d-amphetamine in rats: working memory, tolerance,
and extinction. Psychopharmacology (Berl), 170(2), 150-156.
Shoblock, J. R., Maisonneuve, I. M., & Glick, S. D. (2004). Differential interactions
of desipramine with amphetamine and methamphetamine: evidence that

64

amphetamine releases dopamine from noradrenergic neurons in the medial
prefrontal cortex. Neurochem Res, 29(7), 1437-1442.
Shoptaw, S., Reback, C. J., Peck, J. A., Yang, X., Rotheram-Fuller, E., Larkins, S.,
et al. (2005). Behavioral treatment approaches for methamphetamine
dependence and HIV-related sexual risk behaviors among urban gay and
bisexual men. Drug Alcohol Depend, 78(2), 125-134.
Siegel, S. (1977). Learning and psychopharmacology. In J. ME (Ed.),
Psychopharmacology in the practice of medicine. (pp. 61-70). New York:
Appleton-Century-Crofts.
Smith, A. D., & Bolam, J. P. (1990). The neural network of the basal ganglia as
revealed by the study of synaptic connections of identified neurones. Trends
Neurosci, 13(7), 259-265.
Spyraki, C., Fibiger, H. C., & Phillips, A. G. (1982). Dopaminergic substrates of
amphetamine-induced place preference conditioning. Brain Res, 253(1-2),
185-193.
Stewart, J. (1992). Neurobiology of conditioning to drugs of abuse. Ann N Y Acad
Sci, 654, 335-346.
Sulzer, D., Chen, T. K., Lau, Y. Y., Kristensen, H., Rayport, S., & Ewing, A. (1995).
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol
and promotes reverse transport. J Neurosci, 15(5 Pt 2), 4102-4108.
Teng, L., Crooks, P. A., & Dwoskin, L. P. (1998). Lobeline displaces
[3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal
synaptic vesicles: comparison with d-amphetamine. J Neurochem, 71(1),
258-265.
Teng, L., Crooks, P. A., Sonsalla, P. K., & Dwoskin, L. P. (1997). Lobeline and
nicotine evoke [3H]overflow from rat striatal slices preloaded with
[3H]dopamine: differential inhibition of synaptosomal and vesicular
[3H]dopamine uptake. J Pharmacol Exp Ther, 280(3), 1432-1444.
Tzschentke, T. M. (1998). Measuring reward with the conditioned place preference
paradigm: a comprehensive review of drug effects, recent progress and new
issues. Prog Neurobiol, 56(6), 613-672.
Tzschentke, T. M. (2007). Measuring reward with the conditioned place preference
(CPP) paradigm: update of the last decade. Addict Biol, 12(3-4), 227-462.

65

Van der Kooy, D. (1987). Place conditioning: A simple and effective method for
assessing the motivational properties of drugs. In M. A. Bozarth (Ed.),
Methods of assessing the reinforcing properties of abused drugs. (pp. 229240). New York: Springer-Verlag.
Venton, B. J., Seipel, A. T., Phillips, P. E., Wetsel, W. C., Gitler, D., Greengard, P.,
et al. (2006). Cocaine increases dopamine release by mobilization of a
synapsin-dependent reserve pool. J Neurosci, 26(12), 3206-3209.
Vocci, F. J., & Appel, N. M. (2007). Approaches to the development of medications
for the treatment of methamphetamine dependence. Addiction, 102 Suppl 1,
96-106.
Volkow, N. D., Wang, G. J., Telang, F., Fowler, J. S., Logan, J., Childress, A. R., et
al. (2006). Cocaine cues and dopamine in dorsal striatum: mechanism of
craving in cocaine addiction. J Neurosci, 26(24), 6583-6588.
Vollm, B. A., de Araujo, I. E., Cowen, P. J., Rolls, E. T., Kringelbach, M. L., Smith,
K. A., et al. (2004). Methamphetamine activates reward circuitry in drug naive
human subjects. Neuropsychopharmacology, 29(9), 1715-1722.
Watson, C. J., Venton, B. J., & Kennedy, R. T. (2006). In vivo measurements of
neurotransmitters by microdialysis sampling. Anal Chem, 78(5), 1391-1399.
Wellman, P. J., Elliott, A. E., Barbee, S., Hollas, C. N., Clifford, P. S., & Nation, J. R.
(2008). Lobeline attenuates progressive ratio breakpoint scores for
intracranial self-stimulation in rats. Physiol Behav, 93(4-5), 952-957.
Westerink, B. H. (1995). Brain microdialysis and its application for the study of
animal behaviour. Behav Brain Res, 70(2), 103-124.
White, F. J., & Kalivas, P. W. (1998). Neuroadaptations involved in amphetamine
and cocaine addiction. Drug Alcohol Depend, 51(1-2), 141-153.
Wilhelm, C. J., Johnson, R. A., Eshleman, A. J., & Janowsky, A. (2008). Lobeline
effects on tonic and methamphetamine-induced dopamine release. Biochem
Pharmacol, 75(6), 1411-1415.
Yokel, R. A., & Pickens, R. (1973). Self-administration of optical isomers of
amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther,
187(1), 27-33.

66

Yokel, R. A., & Wise, R. A. (1976). Attenuation of intravenous amphetamine
reinforcement by central dopamine blockade in rats. Psychopharmacology
(Berl), 48(3), 311-318.
Yokel, R. A., & Wise, R. A. (1978). Amphetamine- type reinforcement by
dopaminergic agonists in the rat. Psychopharmacology (Berl), 58(3), 289296.
Zetterstrom, T., Sharp, T., Collin, A. K., & Ungerstedt, U. (1988). In vivo
measurement of extracellular dopamine and DOPAC in rat striatum after
various dopamine-releasing drugs; implications for the origin of extracellular
DOPAC. Eur J Pharmacol, 148(3), 327-334.
Zhang, M. Y., & Beyer, C. E. (2006). Measurement of neurotransmitters from
extracellular fluid in brain by in vivo microdialysis and chromatography-mass
spectrometry. J Pharm Biomed Anal, 40(3), 492-499.
Zheng, G., Dwoskin, L. P., & Crooks, P. A. (2006). Vesicular monoamine
transporter 2: role as a novel target for drug development. AAPS J, 8(4),
E682-692.

67

VITA
Name:

Nichole Marie Neugebauer

Date of birth:

August 25, 1979

Place of birth:

Parkston, South Dakota

Education:
8/02-present University of Kentucky at Lexington
Master of Science in Psychology, May 2005
8/98-5/01

University of Massachusetts at Boston
Bachelor of Science in Psychology
Minor in Biology
Magna Cum Laude, May 2001

1/97-5/98

University of South Dakota at Vermillion
Major: Psychology

Professional Positions:
8/02-8/08
University of Kentucky, Lexington, KY
Graduate Student/Research Assistant with Dr. M.T. Bardo in
Behavioral Pharmacology and Psychopharmacology Program
Department of Psychology
8/01-8/02

University of Kentucky, Lexington, KY
Sr. Laboratory Technician with Dr. L.P. Dwoksin
College of Pharmacy

9/99-5/01

University of Massachusetts, Boston, MA
Undergraduate Research and Teaching Assistant with Dr. S.T.
Cunningham in Department of Psychology

Scholastic and Professional Honors:
University of Kentucky, Lexington, KY
Interdepartmental Neuroscience Program Fellowship (2002-2003)
Graduate School Research Travel Awards (2003-2005, 2007)
NIDA Predoctoral Research Training Grant: T32 DA07304 (Behavioral
Science; 2004-2006)
The College on Problems of Drug Dependence Travel Award (June 2005)
Research Challenge Trust Fellowship Travel Award (September 2005)
NIDA Predoctoral Research Training Grant: T32 DA016176 (Biochemistry;
2006-2008)
Behavioral Neuroscience and Psychopharmacology Graduate Student
Achievement Award (2006, 2008)

68

University of Massachusetts, Boston, MA
Departmental Honors in Psychology
Dean’s List: Fall 1998- Spring 2001
Honor Societies: Psi Chi, Golden Key
Undergraduate Research Fund Award (1999-2001)
Associate Provost and Honors Department 1/2000, 1/2001 and 6/2001
Publications:
Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z,
Bardo MT and Crooks PA (in press). Targeting reward-relevant nicotinic
receptors in the discovery of novel pharmacotherapeutic agents to treat
tobacco dependence. In R. A. Bevins and A. R. Caggiula (Eds.), The
motivational impact of nicotine and its role in tobacco use.
Wooters TE, Neugebauer NM, Rush CR, Bardo MT. (2008) Methylphenidate
enhances the abuse-related behavioral effects of nicotine in rats: intravenous
self-administration, drug discrimination, and locomotor cross-Sensitization.
Neuropsychopharm. 33(5):1137-48.
Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P,
Papke RL, Bardo MT, Crooks PA. (2007) Discovery of a novel nicotinic
receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)12-triethylammonium-dodecane dibromide (TMPD). Biochem Pharmacol.
74(8):1271-82.
Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, Bardo MT.
(2007) Lobelane decreases methamphetamine self-administration in rats.
Eur J Pharmacol. 571(1):33-8.
Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP and Bardo
MT. (2007)The effects of a novel nicotinic receptor antagonist N,Ndodecane-1,
12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotineinduced increases in extracellular dopamine in rat nucleus accumbens.
Neuropharmacology 52(3): 755-763.
Stairs DJ, Neugebauer NM, Wei X, Cassis L, Crooks PA, Dwoskin LP and Bardo
MT. (2007) Enantomeric effects of nornicotine on intravenous nicotine selfadministration, dopamine metabolism, and cardiovascular function in rats.
Psychopharmacology Feb; 190(2):145-55.
Neugebauer NM , Zhang J, Crooks PA, Dwoskin LP and Bardo MT. (2006)
Effect of a novel nicotinic receptor antagonist, N,N’-dodecane-1,12-diyl-bis-3picolinium dibromide (bPiDDB), on nicotine self-administration and
hyperactivity in rats. Psychopharmacology Feb;184(3-4):426-34.

69

Neugebauer NM, Cunningham ST, Bryant RI, Zhu J, Middleton L and Dwoskin
LP. (2004) Effects of environmental enrichment on behavior and dopamine
transporter function in medial prefrontal cortex in adult rats prenatally treated
with cocaine. Dev Brain Res. Nov 25;153(2):213-23.
Rauhut AS, Neugebauer NM, Dwoskin LP and Bardo MT. (2003) Effect of
bupropion on nicotine self-administration in rats. Psychopharmacology
169(1):1-9.

Nichole Marie Neugebauer
________________________________
07/16/2008
________________________________

70

